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CHAPTER 1: INTRODUCTION
1.1 DCIS (Ductal Carcinoma In situ)
Mortality from breast cancer has declined for the past two decades, and this
decline (Siegel, Naishadham et al. 2012) was thought due to both introduction of
screening programs in the 1980s, resulting in earlier diagnosis and intervention (Kopans
2011, Puliti and Zappa 2012), and the development and optimization of chemotherapy
(Early Breast Cancer Trialists' Collaborative, Peto et al. 2012). Meta-analysis of 11
randomized clinical trials with 13 years follow-up estimated reduction of 20% of cancer
in women invited for screening (Independent 2012).
DCIS (Ductal Carcinoma in situ) accounts for 15%-25% of newly diagnosed
breast cancer cases in the United States (Polyak 2010). DCIS, by definition, is a noninvasive cancer.

It is characterized by the accumulation of abnormal cells in the

mammary duct without invasion into the basement membrane and into the stroma
(Burstein, Polyak et al. 2004). Unlike the dramatic improvement in the detection of
DCIS, the molecular mechanisms that govern the progression to invasive phenotype are
shrouded in mystery. Until 1980, DCIS represented less than 1% of breast cancer (Van
Cleef, Altintas et al. 2014).

Apparent incidence has increased, in part, due to the

increasing use of mammography screens and improved imaging technologies (Kuerer,
Albarracin et al. 2009). This means that more DCIS lesions are detected earlier and
more frequently due to improvements in imaging technology (i.e., mammograms).
Overdiagnosis is a direct result of mammography and is manifested by the
dramatic increase in DCIS (Gotzsche and Nielsen 2011, Gotzsche, Jorgensen et al.
2012). Overdiagnosis refers to a detection of subclinical disease that, if left untreated,
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would not cause symptoms or death. The National Institutes of Health Office of Medical
Application Research commissioned a review on the incidence, treatment and
outcomes of DCIS (Virnig, Tuttle et al. 2010). The results led to the conclusion that the
incidence of DCIS has risen from 1.87 per 100,000 in 1973 to 3.25 in 100,000 in 2004,
with the increase mostly accounted for by the introduction of screening mammography
(Virnig, Tuttle et al. 2010). Recently, Welch et al. used 1975-2012 data from the SEER
(Surveillance, Epidemiology and End Results) database to calculate the tumor-size
distribution and size specific incidence of breast cancer among women 40 years and
older (Welch, Prorok et al. 2016). They concluded that after the introduction of
screening, the proportion of detected breast tumors that were small (invasive tumors
measuring <2 cm or in situ tumors) increased from 36% to 68%. The proportion of
detected tumors that were large (invasive tumors measuring ≥ 2 cm) was decreased
from 64% to 32%. The authors concluded that although the rate of detection of large
tumors fell after the introduction of screening, this distribution was primarily the result of
additional detection of small tumors. They add that women are more likely to have
breast cancer overdiagnosed than have earlier detection of a tumor that was destined to
grow in size.
Some DCIS, if left untreated, will rapidly progress to invasive cancer and/or recur
following treatment whereas others will remain indolent (not grow or progress to an
invasive disease that may require therapeutic intervention). Thus, once DCIS is
detected, treatment is frequently offered to women even though the majority present
with an indolent form of DCIS (Sanger, Engels et al. 2014), resulting in overtreatment.
Overdiagnosis leads to overtreatment that may not benefit the patient and can
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potentially harm her because of overdiagnosed disease. The “harm” is the cost to a
woman’s mental (anxiety) and physical well-being (i.e., side effects from unnecessary
treatment). A consequence of overdiagnosis is that in some cases, women have their
cancer treated by surgery, radiation therapy or medication, but neither the woman nor
the physician can know whether this cancer would be the one that could possibly lead to
death or one that would have remained undetected for the rest of the woman’s life
(Independent 2012).

An indolent DCIS, if left alone, is less likely to threaten the

patient’s health within her lifetime and therefore does not require treatment (Kaur, Mao
et al. 2013). The current recommended treatment for DCIS is wide excision
lumpectomy, with or without radiation, mastectomy or hormone therapy after surgery
(http://www.breastcancer.org). Out of 496,488 women diagnosed with DCIS, 33.4%
had a single mastectomy and 7.0% had a contralateral prophylactic mastectomy
(removal of the opposite healthy breast) (Wong, Freedman et al. 2016).
The issue of overdiagnosis and overtreatment has led to the launching of clinical
trials that address the management of low risk DCIS.

For example, LORD

(Management of Low-risk DCIS), sponsored by the European Organization for
Research and Treatment of cancer, is a randomized, international, multicenter phase III
trial that aims to determine whether screen-detected low-grade DCIS can safely be
managed by an active surveillance strategy or conventional treatment (radiation) over a
10 year period. The primary outcome is an ipsilateral recurrence (defined by location on
the same side as primary lesion) and survival without invasive breast cancer
(https://clinicaltrials.gov/ct2/show/NCT02492607?term=DCIS). This new trial is just
beginning to accrue patients and so results are not available. Another recent project,
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named WISDOM (Women Informed to Screen Depending on Measures Risk) aims to
investigate whether a an individualized (tailored to the individual patient; based on
family history) approach to breast cancer screening is as safe and effective as annual
mammograms (J. Clin Oncol 34, 2016 suppl; abstr e 13035). Therefore, it is important
to distinguish between which lesions will progress to invasive breast cancer, and to
illuminate the pathways that drive the progression to IDC (invasive ductal cancer).
Additional clinical trials address the efficacy of current treatment options, such as the
sole employment of wide-excision without radiation therapy for treatment of small DCIS
of grade 1-2 (https://clinicaltrials.gov/ct2/show/NCT00165256).
DCIS is heterogeneous, expressing a variety of markers such ER (Estrogen
Receptor), PR (Progesterone Receptor), HER2/ERBB2 (Human Epidermal Growth
Factor Receptor), etc. To address this heterogeneity, multiple clinical trials have been
designed to assess the treatment of DCIS, tailored to the expression of these markers.
For example, clinical trials evaluating the treatment of HER2/EGFR expressing DCIS (of
high grade) with lapatinib were designed to test the inclusion of lapatinib treatment as
an interval between biopsy diagnosis and surgery. This study was terminated due to
low accrual (https://clinicaltrials.gov/ct2/show/NCT00555152?term=DCIS&rank=21).
Meta-analyses have also been performed on multiple studies focusing on DCIS.
Analyses were performed by the Cochrane Breast Cancer Group in 2013 on four
randomized controlled trials totaling of 3925 women. They compared treatment with
breast conserving surgery alone vs. breast conserving surgery with the addition of
radiation therapy. The results suggested that the addition of radiation therapy reduced
the risk of recurrence of either DCIS or breast cancer in the treated breast by 51%, with
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no long-term toxicity from radiotherapy (Goodwin, Parker et al. 2013). Another review,
published in 2012 by the same group, examined whether women taking tamoxifen lived
longer compared to those who did not take hormone therapy after local excision. The
findings were based on two large studies with 3375 participants. The review states that
even though administration of tamoxifen after local excision of DCIS reduced the risk of
DCIS recurrence, it did not reduce the risk of overall mortality (Staley, McCallum et al.
2012). The results of other clinical trials suggest that treatment of DCIS with adjuvant
tamoxifen may be beneficial to DCIS patients. A NSABP (National Surgical Adjuvant
Breast and Bowel Project) B24 study was performed to retrospectively evaluate the
benefits of adjuvant tamoxifen in patients with DCIS after lumpectomy and radiation
(Allred, Anderson et al. 2012). The results of the study suggest that treatment of DCIS
with tamoxifen after lumpectomy and radiation conferred benefit to patients with ER+
DCIS.

Patients with ER-positive DCIS treated with tamoxifen (vs placebo) showed

significant decrease in subsequent breast cancer at 10 years. No significant benefit was
observed in ER- DCIS. One thousand seven hundred and ninety-nine patients were
recruited. The absolute risk of ipsilateral or contralateral recurrence was reduced from
19 per 1000 women to 6 per 1000 women. These data suggest that adding tamoxifen
post-lumpectomy/radiation may benefit patients.
Previous expression profiling studies have demonstrated that very few genes are
differentially expressed between DCIS and invasive breast cancer of similar grade (Ma,
Salunga et al. 2003, Porter, Lahti-Domenici et al. 2003, Chin, de Solorzano et al. 2004,
Sgroi 2010). A few include COX2, Ki67 and pRB (Polyak 2010). Our previous RNAseq
studies also found down-regulation of DST, HSRA1 and TGFBI in the progression to
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DCIS (Kaur, Mao et al. 2012), which is in agreement with other studies (Calaf, EchiburuChau et al. 2008, Lee, Stewart et al. 2012, Wang, Eckert et al. 2012).

Molecular

screening approaches have been developed, and they are useful in making informed
decisions about post-surgery adjuvant treatments or recurrence (Rudloff, Jacks et al.
2010). A subset of markers from the 21 gene Oncotype DX® test can predict the
likelihood of progression (Solin, Gray et al. 2013). A recent pooled analysis of four
prospective studies regarding the application of Oncotype DX to ER+ HER2- patients
has been performed. The conclusion was that employment of this test led to the
decrease in chemotherapy recommendation rate by 11% (from 55% to 44%).

The

highest change in chemotherapy recommendation rates were in patients who would
have been originally recommended for chemotherapy for grade 2 tumors (Albanell,
Svedman et al. 2016). The Oncotype DX DCIS Score –short form estimates the risk of
ipsilateral breast recurrences in patients with DCIS treated with breast conserving
surgery without adjuvant radiation therapy.

Recent studies were also designed to

evaluate the cost effectiveness of using the Oncotype DX DCIS score in the treatment
of women diagnosed with DCIS. The authors concluded that even though usage of the
DCIS score lowered the proportion of women undergoing radiation therapy,
incorporation of the DCIS score was not cost effective (Raldow, Sher et al. 2016). The
authors emphasize the importance of engaging patients in the complex and
controversial decision making process.
In the traditional breast cancer progression model, invasive breast cancers were
thought to rise through a stepwise linear progression from normal breast epithelium to
hyperplasia to atypical hyperplasia to ductal carcinoma in situ to invasive breast cancer,
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resulting from progressive accumulation of genetic mutations in epithelial tissue. This
progression model has been supported by human clinical and epidemiological data and
by molecular clonality studies addressing the relationships between in-situ and invasive
areas of the same tumor and DCIS and local invasion (Polyak 2010). Other models of
breast cancer progression are proposed.

For example, the non-linear or branched

progression models propose that DCIS would be a precursor to IDC, but different
grades of DCIS would progress to IDCs of the same grade (Wellings and Jensen 1973).
Another model of progression proposes that DCIS and IDC could develop from
the same progenitor cell and progress independently (Sontag and Axelrod 2005). Some
evidence suggests that DCIS may even regress. Histological studies performed on high
grade DCIS show evidence of regression. This is possibly due to factors such as
fibrosis, chronic inflammation, and the presence of periductal T cells that elicit a
targeted immune response to certain lesions (Wasserman and Parra-Herran 2015).
The authors also suggest that an immune response is likely to eradicate those tumors
with high immunogenicity, thus selecting for less immunogenic clones.
Analysis of clinical specimens has revealed several features of DCIS that are
associated with progression to invasive cancer (Knudsen, Ertel et al. 2012, Lee, Stewart
et al. 2012). Gene profiling studies from several groups comparing DCIS to invasive
breast cancer have shown that gene expression programs associated with EMT
(epithelial to mesenchymal transition) are associated with invasive breast cancer
(Knudsen, Ertel et al. 2012, Lee, Stewart et al. 2012, Witkiewicz, Cox et al. 2014). One
conclusion from these results is that DCIS undergoing EMT would have the propensity
to progress in invasive disease.

Cell-cell junctions and basal attachment to the
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membrane are lost during the process of EMT and are associated with invasive disease
(Witkiewicz, Cox et al. 2014).
Interestingly, other reports also indicate that epigenetic alterations and tumor
environment play a role in DCIS progression. Analysis of bulk and micro-dissected
tissues has suggested that genes differentially expressed between DCIS and IDC are
enriched for changes in processes related to the tumor microenvironment (Lee, Stewart
et al. 2012, Vargas, McCart Reed et al. 2012). Additional reports have provided
evidence that epigenetic changes (Widschwendter and Jones 2002, Fleischer, Frigessi
et al. 2014) contribute to DCIS progression, and may be mediated by myoepithelial cells
(Hu, Yao et al. 2008).
It is important to mention that breast cancer has been characterized into 5
different subtypes, with distinct molecular features.

Sorlie et al reported a distinctive

“molecular portrait” of breast cancer using 456 cDNA clones (Perou, Sorlie et al. 2000,
Sorlie, Perou et al. 2001). The tumors were classified into five intrinsic subtypes with
distinct clinical outcomes, i.e., luminal A, luminal B, HER2-overexpression, basal-like
and normal like tumors (Sorlie, Tibshirani et al. 2003). These subtypes have been
validated by IHC (immunohistochemistry) with some exceptions (Parker, Mullins et al.
2009).

Luminal A is characterized as ER (Estrogen Receptor)/PR (Progesterone

Receptor) positive. The luminal B subtype is characterized as ER or PR positive, and
HER2 (Human Epidermal Growth factor receptor 2) positive. HER2 overexpressing
types are characterized by HER2 enrichment, while being ER/PR negative. Basal like
breast cancer is characterized as triple negative. These subtypes have been associated
with different prognoses. Patients with luminal A tumors have the best prognosis and
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patients with basal like breast cancer have the worst prognosis. Patients can be
separated for treatment options based on their subtypes (Hon, Singh et al. 2016). This
classification relates to the types of patient-derived breast cancer cell lines used in this
dissertation. For example, MCF-7 and T47-D are invasive breast cancer cell lines of
luminal A subtype; they express both ER and PR without HER2 amplification (Neve,
Chin et al. 2006, Prat, Parker et al. 2010). MDA-MB-231, BT-549 and Hs578t are triple
negative basal breast cancer cell lines (Neve, Chin et al. 2006, Prat, Parker et al. 2010).
Heterogeneity is also observed in invasive and pre-invasive DCIS with similar
variation in clinicopathological features such as histological grade, ER/PR expression,
HER2/ERBB2 status (Livasy, Perou et al. 2007, Clark, Warwick et al. 2011). This is
particularly important, since reports have proposed that molecular features (gene
signatures) associated with disease progression are unique to intrinsic subtypes
(Lesurf, Aure et al. 2016). For example, invasive gene signatures for the Luminal A
subtype was enriched for immune and cell cycle processes. Luminal B subtypes
contained invasive signature enriched for immune-related responses, cell metabolism
and cell cycle. The invasive signature for the HER2 expressing subtype was enriched
for cell adhesion, ECM-receptor interaction and cell motility (Lesurf, Aure et al. 2016).
These results of this study point to the hypothesis that each specific subtype undergoes
a distinct evolutionary course of disease progression from pre-invasive to invasive
stage.
Deregulation of tumor suppressors has been documented in the progression of
DCIS to invasive breast cancer. Rb (retinoblastoma) is a key negative regulator of
proliferation and connects multiple signaling pathways to cell cycle machinery (Cobrinik
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2005, Knudsen and Knudsen 2008). Studies have indicated that the disruption of the
Rb tumor suppressor pathway is significantly associated with recurrence and disease
progression of DCIS in multiple independent cohorts.

The analysis of the cohorts

included direct staining and use of surrogate markers such as p16ink4a and Ki67
(Gauthier, Berman et al. 2007, Ertel, Dean et al. 2010, Kerlikowske, Molinaro et al.
2010, Knudsen, Pajak et al. 2012). However, Rb disruption alone may not be sufficient
and might require overexpression of an oncogene, such as ErbB2. Studies indicate that
ErbB2 over expression is frequently found in DCIS; one study documented ErbB2
overexpression in more than half of the DCIS cases analyzed (Allred, Clark et al. 1992,
Hoque, Sneige et al. 2002). Studies have implicated the cooperation of loss of the Rb
pathway and ErbB2 over-expression in specifically driving DCIS progression by
deregulation of mammary cell proliferation, acinar morphology (Witkiewicz, Cox et al.
2014). This is one instance in which loss of tumor suppression and over-expression of
oncogenes together drive the progression of DCIS to invasive breast cancer.
1.2 MCF10 Progression Series
The MCF10 progression series has been employed for this dissertation research.
The model of the MCF10 family of cell lines was developed by investigators at the
Michigan Cancer Foundation, now known as Karmanos Cancer Institute. The basis of
the model is the human cell line of MCF10A, which was isolated from breast tissue,
showing very mild, hyperplastic changes and extensive fibrocystic phenotype.

This

breast tissue was from a 36-year-old woman who was in good health with no evidence
of malignancy (Miller, Soule et al. 1993). MCF10A is one of the series of cell lines that
was established by the spontaneous immortalization of the original, mortal cultures.
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These cells, though immortalized, grow in a confined monolayer with contact inhibition.
The transformed MCF10.Neo T cell line was then derived from the MCF10A after
transfection with mutated T24 H-ras. When injected into immunodeficient nude mice,
the MCF10.Neo T cells develop into a series of cell lines, including MCF10.AT1 and
MCF10.DCIS (Miller, Soule et al. 1993, Dawson, Wolman et al. 1996). MCF10.Neo T
cells form small flat nodules (Dawson, Wolman et al. 1996). MCF10.CA1d cell line is
one of five tumorigenic cell lines derived from xenografts after trocar transplantation of
organoids. The organoids were derived from transplantation of MCF10AT1K.cl2 cells
into mice. The other cell lines are MCF10.CA1a, MCF10.CA1b and MCF10.CA1c
(Santner, Dawson et al. 2001). MCF10.CA1d cells have been employed in this project.
1.3 Next Generation Sequencing and Rap1Gap
High throughput gene expression analysis has been used to identify genes that
may be up or down-regulated throughout the premalignant and malignant progression of
breast cancer. Previously, NGS (next generation sequencing) was performed on RNA
samples obtained from the Mattingly and Sloane laboratories from cells grown on rBM
(reconstituted basement membrane). The purpose was to identify a panel of genes that
could be involved in development of DCIS. Three different models of DCIS were used
(MCF10.DCIS, SUM 102 and SUM 225) in comparison to MCF10A (representing nontransformed breast epithelium). SUM 102 was derived from a surgical resection of a
DCIS with micro-invasion and SUM 225 was derived from a chest wall recurrence in a
patient originally diagnosed with DCIS (Ethier, Mahacek et al. 1993, Ethier 1996). Data
analysis was performed by the Krawetz laboratory. By comparing the number of reads
on each gene in three DCIS cell lines with that in the control MCF10A cells, the
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expression of 157 genes was found to be significantly altered (fold change > 4) with 63
being increased in expression in all three DCIS cell lines. Fig. 1.1 is a Venn diagram of
results from mRNA-Seq analysis of three models of DCIS compared to MCF-10A, which
have been published (Kaur, Mao et al. 2012). The 63 significantly increased genes
common to all three DCIS cell lines included Rap1Gap, a negative regulator of Rap1
GTPase activating protein. Genomatix analysis was used to further analyze the mRNA
seq results to gain insights into the common frameworks in the promoter regions of the
63 upregulated genes that were found in all three models of DCIS. From a total of
82,703 modules queried in the entire human genome, 244 promoter loci were found to
be associated with these 63 up-regulated genes. Enrichment analysis (represented in
Table 1) showed that the common framework (predicted cluster of regulating
transcription factors) RXRF-ZF02-ZF02-PLAG-HDBP is highly enriched [336-fold] in our
data-set, present in the promoters of RAP1GAP, SPRY4 and PDGFB genes (Kaur, Mao
et al. 2012).
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Figure 1.1: Venn diagram showing the results of microarray analysis of the three
models of DCIS: MCF10.DCIS, SUM 102 and SUM 225.
There are a total of 157 genes that are consistently differentially expressed in MCF10A
vs. DCIS models.
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Table 1: Common framework as analyzed by the Genomatix tool.
The numbers highlighted in yellow represent the significantly enriched promoter
elements for the 63 upregulated genes. Marked in red, the RXRF-ZF02-PLAG-HDBP
framework was highly enriched on the Rap1Gap promoter (with an enrichment of 336).
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1.4 Rap1Gap
Rap1Gap is a member of a family of GTPase activating proteins (GAPs) that
facilitate GTP hydrolysis of Rap1 GTPases (Raaijmakers and Bos 2009). The Rap1Gap
gene, which lies at 1p36-p35 in the human, is conserved in many species, including
Drosophila melanogaster, Caenorhabditis elegans, Anopheles gambia, Mus musculus,
Rattus

norvegicus

and

Homo

http://www.ncbi.nlm.nih.gov/homologene?term=RAP1GAP).

sapiens
Rap1Gap

(from:
protein

is

expressed in a variety of normal human tissues. Rap1Gap is abundantly expressed in
the cerebral cortex, adrenal gland, salivary gland, lung, liver and gall bladder.
(http://www.proteinatlas.org/ENSG00000076864-RAP1GAP/tissue).

Rap1Gap protein

is also expressed in thyroid follicular cells (Tsygankova, Prendergast et al. 2007),
pancreatic ductal cells (Zhang, Chenwei et al. 2006) and colonic epithelial cells
(Tsygankova, Ma et al. 2010).
Rap1Gap is involved in a variety of cellular processes. Some of these processes
are proliferation, adhesion and morphogenesis (Altschuler and Ribeiro-Neto 1998,
Asha, de Ruiter et al. 1999, Zhang, Chenwei et al. 2006). Introduction of Rap1Gap has
been shown to cause delay in G1-S transition (Zhang, Mitra et al. 2006). In addition to
its role in cell proliferation, Rap1Gap is involved in integrin-mediated cell adhesion
(Caron, Self et al. 2000, Reedquist, Ross et al. 2000). In thyroid cancer cell lines,
silencing of Rap1Gap alters the distribution of E-cadherin, β catenin and p120 catenin
by reducing their accumulation at adherens junctions (Tsygankova, Ma et al. 2010).
1.4.1 Rap1Gap in Cancer
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Rap1Gap has been investigated in epithelial solid tumors such as melanoma,
prostate, pancreatic cancer, squamous cell carcinoma and thyroid cancer (Weiss, Biwer
et al. 1997, Zhang, Chenwei et al. 2006, Tsygankova, Prendergast et al. 2007, Bailey,
Kelly et al. 2009, Zheng, Gao et al. 2009, Zuo, Gandhi et al. 2010). qPCR studies in
pancreatic cancer show that while Rap1Gap was expressed in normal pancreatic tissue,
it was not present in pancreatic adenocarcinomas. The authors suggest that inactivation
of Rap1Gap may not be critical to early pancreatic cancer development (Zhang,
Chenwei et al. 2006) and may be involved in later stages of tumor progression (Zhang,
Chenwei et al. 2006). Similar studies in prostate cancer implicate Rap1 activation in the
promotion of prostate cancer metastasis.

In addition, increase in Rap1 activity (or

decrease in Rap1Gap) was observed in invasive prostate cancer cell lines, such as DU145, PC3 and PC3-M cell lines and that active Rap enhances migration and invasion via
activation of integrins (Bailey, Kelly et al. 2009). Other work on Rap1Gap in melanoma,
thyroid and squamous cell carcinoma shows that Rap1Gap loss increased cell
proliferation, survival, migration and invasion and that loss of Rap1Gap occurs through
epigenetic silencing and LOH (loss of heterozygosity) (Zheng, Gao et al. 2009, Zuo,
Gandhi et al. 2010, Banerjee, Mani et al. 2011). LOH is a common genetic event in
many cancer types and is defined as one of the early observations of a change in
polymorphic markers from a heterozygous state in the germline to an apparently
homozygous state of DNA in cancer cells (Ryland, Doyle et al. 2015). Epigenetic gene
silencing refers to non-mutational gene inactivation that can be faithfully propagated
from precursor cells to clones of daughter cells.

The addition of methyl groups to
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cytosine residues in CpG dinucleotides in DNA is a mechanism through which
epigenetic silencing is achieved (Tycko 2000).
1.4.2 Rap1Gap: A Potential Tumor Suppressor
Research suggests that since Rap1Gap is frequently lost in several tumor types,
it may function as a tumor suppressor (Tsygankova, Feshchenko et al. 2004). For
example, LOH of the Rap1Gap gene is present in a significant number of pancreatic
tumors (Zhang, Chenwei et al. 2006). Loss of Rap1Gap function promotes growth,
survival and invasion of pancreatic cancer cells in vitro and in vivo (Zhang, Chenwei et
al. 2006). In addition, studies on primary thyroid tumor cell lines show that Rap1Gap
expression is lost at a higher frequency in more aggressive tumor types via promoter
hypermethylation and LOH (Zuo, Gandhi et al. 2010). Studies in prostate cancer
indicate that activation of Rap1 induced prostate cancer cell migration and invasion and
enhanced the rate and incidence in mouse xenograft models. Re-expression of
Rap1Gap in aggressive prostate cancer cells impaired migration and invasion (Bailey,
Kelly et al. 2009). In squamous cell carcinoma of head and neck, Rap1Gap is shown to
inhibit proliferation (Zhang, Mitra et al. 2006), invasion (Mitra, Goto et al. 2008) and
progression though the cell cycle. In-vivo studies indicate that human squamous cell
carcinoma cells transfected with Rap1Gap produced significantly smaller tumors in mice
(Zhang, Mitra et al. 2006). In leukemia, Rap1Gap also has been shown to promote
apoptosis (Qiu, Qi et al. 2012). Taken together, in multiple models, Rap1Gap is lost
(epigenetic silencing or LOH) in aggressive cancer cell lines and tumors. Re-expression
of Rap1Gap inhibits cell proliferation and passage through the cell cycle. Experiments
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in pancreatic cancer in-vivo mouse models indicate that introduction of Rap1Gap
inhibits tumor formation, tumor size and metastasis (Zhang, Chenwei et al. 2006).
Tumor suppressors serve as transducers of anti-proliferative signals and inhibit
cell cycle progression. Tumor suppressors also exert their effects through induction of
apoptosis and end mitotic differentiation (Weinberg 1991). An important characteristic
of tumor suppressor genes is that they are lost in many cancer types, such as
melanoma, breast, small cell lung cancer, bladder cancer, retinoblastoma, colorectal
cancer etc. (Klein 1987, Kaden, Gadi et al. 1989, Kaden, Bardwell et al. 1989).
Rap1Gap possesses the majority of these well-studied characteristics, which suggests
that Rap1Gap may function as a tumor suppressor.
1.5 Rap1Gap mRNA transcripts are highly expressed in MCF10.DCIS
The previous NGS results and Genomatix analysis revealed increased Rap1Gap
transcript levels in MCF10.DCIS compared to MCF10A, thus indicating that Rap1Gap
could be as a pivotal factor in the development of DCIS (Kaur, Mao et al. 2013).

In

order to validate the mRNA seq analysis, qPCR (quantitative polymerase chain
reaction) was performed on mRNA extracted from the MCF10 cell series grown in 2D.
The MCF-7 cell line served as the appropriate positive control for initial characterization
of Rap1Gap. This information was obtained from abstract #3840 presented at the 102nd
AACR meeting in Orlando Florida, which indicated that Rap1Gap is highly expressed in
MCF-7 cells. This work was done by the Meinkoth laboratory, focused on Rap1Gap in
thyroid colon cancer cells.

As seen in Figure 1.2, mRNA expression levels in

MCF10.DCIS are high compared to MCF10A.

However, interestingly, mRNA

expression in SUM 102 cells is low, which is does not agree with the original mRNA seq
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analysis. A reason for this discrepancy might be due to the passage number of SUM
102 cells used in the initial mRNA seq analysis vs qPCR study. A repeat of the qPCR
study is necessary to confirm the results. Table 2 depicts the mean CT (Comparative
Threshold) values of Rap1Gap and 18S in the MCF10 progression series.
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A.

Table 2. Mean CT Values of Rap1Gap and 18S
MCF10A

Neo T

AT1

DCIS

CA1d

SUM 102

MCF-7

Rap1Gap

30.36

32.17

32.416

28.71

29.74

33.82

27.54

18S

15.67

16.18

15.04

15.04

15.04

15.04

15.04

Figure 1.2:
series.

Validation of transcriptome data via qPCR of Rap1Gap in MCF10

A. Results of Rap1Gap qPCR analysis of mRNA transcripts from the MCF10 series,
SUM 102 and MCF-7 cultured in 2D. 18S was used to normalize Rap1Gap mRNA
levels. Table 2 shows mean CT values of Rap1Gap and18S in the MCF10 progression
series.
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1.6 Rap1
Rap1 GTPase was first discovered by Kitayama and colleagues in 1989 as a
gene product that normalized a malignant phenotype of K-ras transformed fibroblasts
(Kitayama, Sugimoto et al. 1989). It was discovered later that Rap1 antagonized the
activity of Ras by competing for Raf1, a serine-threonine kinase (Bos 1998). Loss of
function mutations in Rap1 is lethal at the larval stage in Drosophila melanogaster
(Asha, de Ruiter et al. 1999).
Rap1 has two isoforms- Rap1a and Rap1b. Rap1 binds either to GTP or GDP,
and the transition between the two states represents a molecular switch (Takai, Sasaki
et al. 2001).

Endogenous Rap1 is activated through stimulation of various

transmembrane receptors such as receptor tyrosine kinases, heterotrimeric G-protein
coupled receptors, cytokine receptors and cell-cell adhesion molecules. These indirect
upstream activators of Rap1 were discovered after the development of the Rap1 activity
assay, via using Ral GDS-RBD fusion proteins (Franke, Akkerman et al. 1997). Since
Rap is located downstream of so many pathways, it is not surprising that a plethora of
Rap1 “on“ and “off” switches are in place to fine-tune diverse signaling pathways that
are mediated by Rap1. Figure 1.3 is a depiction of the fine-tuned diverse signaling of
Rap1.
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Figure 1.3: Fine-tuned regulation of Rap1.
Image taken with permission from: Nature Reviews Molecular Cell Biology 2, 369377 (May 2001)
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1.6.1“ON”-The activators of Rap1- the GEFs
GEFS, which are guanine nucleotide exchange factors, facilitate the release of
GDP (guanosine diphosphate) allowing Rap1 to bind to GTP. C3G (Crk SH3-domain
binding guanine nucleotide releasing factor) was the first Rap1 specific GEF to be
identified. It specifically mediates Rap1 activation induced by receptor tyrosine kinases
such as those for PDGF and IFNα, the T-cell receptor complex, and ephrin kinase
(Gotoh, Hattori et al. 1995).
Activation of Rap1 through cAMP was initially thought to indicate the possible
involvement of protein kinase A, a target of cAMP. This observation eventually led to
the identification of Epac1 (exchange protein directly activated by cAMP). Epac1 is
activated in vitro and in vivo by direct binding of cAMP (de Rooij, Zwartkruis et al. 1998,
Kawasaki, Springett et al. 1998). In addition to C3G and Epac1, two other types of
GEFs have been characterized; these are the CD-GEFs and the PDZ GEFs (Gloerich
and Bos 2011).
1.6.2 “OFF”- The deactivators of Rap1: the GAPs
Two families of Rap1-specific GAPs sharing a catalytic GAP-related domain
(GRD) have been identified. These are the RapGaps and the SPA-1 family of proteins
(Bos, de Rooij et al. 2001). GAPs enhance the intrinsic GTPase activity of Rap1 to
hydrolyze bound GTP to GDP. Proteins bearing the GRD are conserved in C. elegans
and D. melanogaster, extending to mammals. Figure 1.4 shows the different GAPs and
their domains. Rap1Gap was the first Rap1 specific GAP to be isolated (Polakis,
Rubinfeld et al. 1991).
1.6.3 The Roles of Rap1
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Rap1 has been shown to be activated in response to various growth factors,
cytokines and chemokines that act on receptor tyrosine kinases and G-protein couple
receptors (Bos, de Rooij et al. 2001).
Initial studies following the discovery of Rap1 showed that a dominant active
Rap1 mutant (Rap1V12) attenuated Ras-mediated ERK activation, probably via
competitive interference with c-Raf activation by Ras (Cook, Rubinfeld et al. 1993, Hu,
Kariya et al. 1997). Subsequent studies have indicated that the MAPK-related signaling
pathways controlled by Ras and Rap1 may be spatially and temporally separated
(Mochizuki, Ohba et al. 1999, Zhu, Qin et al. 2002, Ohba, Kurokawa et al. 2003).
Rap1 plays an important role in the regulation of cell-cell adhesion. Functional
studies on Rap1 in testes of Drosophila melanogaster have shown that Rap1 signaling
regulates morphogenic processes through the proper positioning of adherens junctions
(Knox and Brown 2002, Wang, Singh et al. 2006). These results were corroborated by
studies of Rap1 in the control of endothelial barrier function in endothelial cells (Cullere,
Shaw et al. 2005, Fukuhara, Sakurai et al. 2005). Research has shown that while the
activity of Rap1 plays a role in the organization of epithelial polarity in normal human
breast epithelial cells, increased aberrant activation of Rap1, which implies lack of
Rap1Gap control, can lead to tumor formation and progression to malignancy (Itoh,
Nelson et al. 2007).
In addition to cell adhesion, Rap1 plays a major role in various integrin-mediated
biological processes, such as immunological synapse formation, macrophage
phagocytosis,

chemokine-induced

adhesion

and

transmigration

of

leukocytes,

lymphocyte and dendritic cell homing to peripheral organs, platelet adhesion and
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aggregation, as well as adhesion of several distinct cell lines to various ECM proteins
such as fibronectin, fibrinogen, collagen and laminin. This is in line with studies that
show that In normal and malignant conditions, the functional coordination of E-cadherin
and the integrins is essential for maintenance of cellular architecture and facilitation of
dissemination into the adjacent area of the stroma, especially during ductal branching in
mammary gland development (Wiseman and Werb 2002).
Rap1 regulates recycling, avidity and affinity of integrins that are associated with
the actin cytoskeleton (Retta, Balzac et al. 2006). In human cell lines, Rap1 controls Tcell receptor, CD31 and CD98 induced activation of α 1β2 (Katagiri, Hattori et al. 2000,
Reedquist, Ross et al. 2000, Suga, Katagiri et al. 2001, Katagiri, Hattori et al. 2002,
Sebzda, Bracke et al. 2002), but is also required for Mn+2 or activating antibody-induced
α1β2-mediated adhesion (de Bruyn, Rangarajan et al. 2002).

Thus, Rap1 controls

integrin-mediated cellular functions by modulating inside-out activation processes.
Rap1 is suggested to regulate integrin activation either directly through their polarized
spatial distribution or through the effect of cytoskeleton dynamics (Caron 2003, Katagiri,
Maeda et al. 2003, Bos 2005).
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Figure 1.4: Family of Gaps.
Depicted here is a family of the GAPs, some of which are regulators of Rap1. Circled
in red is Rap1Gap, which is of interest in this dissertation. The GoLoco domain, which
contains the conserved Asp-Gln-Arg triad, is located at the N terminus. This domain,
which plays a direct role in GDP binding, is conserved throughout multiple species of
the animal kingdom. Image taken with permission from: Golrich, M. and Bos. J.L.
2011. Trends Cell Biol. 2011 Oct;21(10):615-23.
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1.7 Regulation of E-cadherin
E-cadherin is a principal effector of cell-cell adhesion and is a critical determinant
of tissue architecture and function in both developing and adult organisms (Wheelock
and Johnson 2003). Therefore, orchestration of E-cadherin functions plays an essential
role in physiological and pathological processes. The cadherins, the hallmark of a fully
differentiated epithelium (Wong and Gumbiner 2003), are single-pass trans-membrane
glycoproteins characterized by a variable number of extra-cellular cadherin domains
that mediate cell-cell adhesion in all solid tissues. In epithelia, E-cadherin is an essential
component of the adherens junctions, which are specialized calcium-dependent
adhesive structures required for formation and maintenance of stable cell-cell adhesion
(Wheelock and Johnson 2003).

β-catenin interacts directly with the cadherin

cytoplasmic tail and α-catenin binds to both β-catenin and actin, connecting the
cadherin-catenin complex to the actin cytoskeleton (Balzac, Avolio et al. 2005).
E-cadherin has also been shown to behave as a tumor suppressor by inhibiting
human mammary and prostate tumor cell invasion (Wong and Gumbiner 2003). In
addition, a direct role of E-cadherin in the suppression of invasion has been
demonstrated by the reversion of undifferentiated, invasive cells to a differentiated
phenotype after the transfection of E-cadherin cDNA in cell culture models (Doki,
Shiozaki et al. 1993). Studies have shown that the strong adhesive properties of Ecadherin prevent cells from dissociating from other cells and migrating into the adjacent
microenvironment. This was shown by using E-cadherin blocking antibodies, which
increased cell invasion (Frixen, Behrens et al. 1991). However, other studies have
shown that suppression of tumor invasion by E-cadherin would be independent of
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adhesion itself, and that adhesion suppressive mechanism of tumor invasion is neither
necessary nor sufficient

(Wong and Gumbiner 2003) for invasion.

Several

immunohistochemical studies have reported a strong correlation between E-cadherin
loss and the initiation and progression of tumors (Berx, Becker et al. 1998). This downregulation is generally due to transcriptional repression; loss of E-cadherin function by
genetic inactivation or epigenetic silencing is a common characteristic of invasive
carcinomas (Lombaerts, van Wezel et al. 2006).
1.8 The role of cytoskeletal remodeling in invasion
The cytoskeleton plays a pivotal role in the various aspects of cell physiologyincluding mitosis, cell division, volume control and cell polarity. It also receives,
integrates and transmits both intracellular and extracellular signals. Cytoskeletal
networks are composed of microtubules, actin and septins, which act as signaling
processors received from the membrane (Bezanilla, Gladfelter et al. 2015). Actin and
vimentin will be of focus in this dissertation, since actin and vimentin re-organization
play an important role in the process of invasion.
1.8.1 Actin
Actin belongs to a family of global multi-functional proteins that form
microfilaments. It participates in many important cellular processes such as muscle
contraction, cell motility, cell division, polarization and cytokinesis (Doherty and
McMahon 2008). Actin defines the “skeleton” of the cell and is responsible for the shape
of the cell (Mattila, Batista et al. 2016) and is spatio-temporally regulated. It also has
emerged as a key player in cellular signaling and is remodeled in order to provide force
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and support for the cellular structures and serve as tracks for vesicle or organelle
movement.
In epithelial cells, actin cortical rings are present and in tight association with cellcell adhesions (Haynes, Srivastava et al. 2011). They are located at the inner surface of
the baso-lateral side (Hofer, Jons et al. 1998). During the process of invasion, cells
may acquire EMT (epithelial to mesenchymal transition)-like characteristics.

These

include the dissolution of cortical rings and re-organization of actin into parallel bundles
or stress fibers and loss of epithelial cell polarity (Haynes, Srivastava et al. 2011).
1.8.2 Vimentin
Vimentin is a type III intermediate filament (IF) protein and is ubiquitously
expressed in normal mesenchymal cells. Like actin, it plays a role in the maintenance of
cellular integrity and provides resistance against stress (Satelli and Li 2011) and
regulates adhesion by controlling the function of integrins (Ivaska, Pallari et al. 2007).
In the context of cancer, increased vimentin expression is observed in a variety of
epithelial cancers and has been strongly correlated with increased tumor growth,
invasion and poor prognosis (Satelli and Li 2011). Vimentin is also known as a
canonical marker of EMT (epithelial to mesenchymal transition), which takes place in
both embryogenesis and metastasis (Hay 2005); expression levels correlate with
mesenchymal cell shape and motility (Mendez, Kojima et al. 2010). Studies in breast
cancer show that vimentin expression is elevated in several aggressive breast cancer
cell lines (Gilles, Polette et al. 2003) and is strongly correlated with increased migration
and invasion of breast cancer cells (Gilles, Polette et al. 2003, Korsching, Packeisen et
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al. 2005). Other studies have documented over expression of vimentin in breast cancer
tissues (Kokkinos, Wafai et al. 2007).
1.9 3D Overlay Culture: An overview
The mammary epithelium is organized into two layers: the luminal epithelial cells
that make milk proteins, and the highly contractile basal, or myoepithelial, cells
surrounding the luminal cells. The myoepithelial cells contact the basal lamina, and
regulate the function and polarity of the apical cells. Much evidence supports the idea
that adhesion to the basal lamina helps to establish cellular polarity (Barcellos-Hoff,
Aggeler et al. 1989, Bissell and Ram 1989). Cell–matrix adhesion regulates mammary
cell structure and function in culture models. For example, inhibition of mammary
epithelial cell contact with the BM (basement membrane) alters morphology, inhibits,
survival, decreases proliferation, and inhibits differentiation (Barcellos-Hoff, Aggeler et
al. 1989). Culturing cells on a reconstituted BM matrix or on laminin restores many of
these functions (Streuli, Schmidhauser et al. 1995). Interaction of mammary cells with
the ECM (extra cellular matrix) is mediated by integrins, and luminal epithelium
expresses the α2β1, α3β1 and α6β1 heterodimers (Prince, Klinowska et al. 2002).
Given the significant body of evidence regarding the influence of the ECM on the
structure and function of mammary epithelial cells, it makes sense to utilize 3D overlay
culture in this project. It is more likely to recapitulate the in vivo milieu. In addition to
interrogation of the effects of the ECM on structure, function and differentiation of
epithelial cells, there are other important applications that will be highlighted at this time.
Culture of cells on an ECM yields more physiologically relevant information about
signaling pathways and drug efficacy.
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The most relevant method of culture of mammary epithelial cells in 3D in rBM
(reconstituted basement membrane) was developed in the Brugge and Bissell
laboratories(Debnath, Muthuswamy et al. 2003, Lee, Kenny et al. 2007). A depiction of
the 3D culture method utilized in this dissertation work is depicted in Figure 1.5. Cells
grown on a matrix are relatively resistant to chemotherapeutic drugs (Weaver, Lelievre
et al. 2002) and studies from our laboratory have found that 3D overlay culture reveals a
critical sensitivity of Ras driven breast cancer models to MEK (MAPK/ERK kinase)
inhibitors that was absent in a 2D microenvironment (Li, Chow et al. 2010). Additionally,
the cross-talk between some signaling pathways is not apparent in 2D- and it is their
growth in a 3D environment that unveils previously unknown dynamics (Wang, Weaver
et al. 1998). Proof of this cross talk is observed in the more pronounced phenotypic
differences between non-transformed and malignant epithelial cells cultured on rBM.
This would be due to the interplay between multiple pathways governing epithelial cell
polarity and organization of the structures (Petersen, Ronnov-Jessen et al. 1992,
Debnath and Brugge 2005, Lee, Kenny et al. 2007). This phenomenon is observed in
this project. Evidence of differences in Src signaling in 2D and 3D environments will be
addressed in Chapter 5.
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Figure 1.5: 3D Overlay Culture: A method that more accurately recapitulates in
vivo microenvironment.
Epithelial cells are plated in rBM (reconstituted basement membrane) and an overlay
added to embed the cells in a 3D matrix. When placed in a 3D environment, cells exhibit
differences in organization of epithelial structures, gene expression profiles and protein
expression. The 3D structures represented here simulate transformed epithelial cells
(MCF10.DCIS).
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1.10 ERK/MAPK
The MAPK (mitogen activated protein kinase) pathway is widely studied. The
classical MAPK pathway consists of RAS, RAF, MEK and ERK. It relays a cascade of
signals which regulate the processes of proliferation, differentiation, growth and
migration (Dhillon, Hagan et al. 2007). Ligand mediated activation of receptor mediated
kinases triggers guanosine triphosphate (GTP) loading of Ras GTPase, which then
recruits Raf kinases to the plasma membrane for activation. Raf then activates MEK1/2,
which in turn activates ERK1/2 (Cargnello and Roux 2011). ERK1/2 activation has
been observed in a wide variety of cancers and is closely associated with cancer
development, migration, invasion and metastasis (Park, Jung et al. 2011).
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CHAPTER 2: METHODS
2.1 Cell Culture: 2D and 3D
MCF10A series of cells were maintained as monolayers in 2D culture at 37°C,
5% CO2 in growth medium: DMEM/F12 (without phenol red) containing 5% horse
serum, 20 ng/ml epidermal growth factor, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 50
U/ml penicillin, and 50 μg/ml streptomycin. For 3D culture, a trypsinized single cell
suspension in a 4-ml volume of the assay medium (DMEM/F12 containing 2% horse
serum, 5 ng/ml EGF, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 50 U/ml penicillin, 50
µg/ml streptomycin, and supplemented with 2% (v/v) of Cultrex) were carefully loaded
on top of the rBM, and will be cultured at 37°C and 5% CO 2, with the medium being
changed every 4 days. 3D structures were fixed or harvested after 8 days of growth.
2.2 Retroviral Infection for shRNA Knockdown
Targeted cell lines for Rap1Gap knockdown were MCF10.DCIS, MCF10.Ca1D,
and T47-D breast cancer cells. HEK293T cells were maintained at 37°C in DMEM
containing 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin and supplemented with 4
mM l-glutamine, and 1 mM sodium pyruvate until 90% confluent. For transfection, the
medium was changed to omit the antibiotics. Then, the cells were triply transfected with
equal amounts of the retrovirus construct, pVPack-GP plasmid, and pVPack-VSV-G
plasmid using Lipofectamine 2000 reagent according to the manufacturer's instructions.
The medium was changed 6 hours after transfection, and the cells were cultured at
37°C for 16 hours when extensive expression of the reporter dsRed proteins could be
monitored by fluorescent microscopy. The medium was changed and the cells were
cultured at 30°C for 24 hours for the production of retroviruses. The virus broth was
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pipetted and centrifuged for 5 minutes at 200g to remove cell debris. Fresh medium was
added and the HEK293 cells were continued to be cultured for 24 hours at 30°C to
harvest a second batch of virus broth.
The supernatant broth containing viruses was supplemented with polybrene at a
final concentration of 12 µg/ml by the addition of a 4 mg/ml polybrene stock solution.
Cells were trypsinized, centrifuged, and resuspended in growth medium to form single
cell suspensions at a concentration of 2 x 106 cells/ml. The cell suspensions were mixed
(3:1 v/v ratio) with virus mixture, plated onto tissue culture dishes at low starting
confluence (typically ~5%), and cultured at 37°C.

The next day, the medium was

changed, and the cells were subjected to a second round of infection using the second
batch of viruses as described above. On the third day, the medium was changed again,
and the culture continued. Virus transduction efficiency was checked using confocal
fluorescent microscopy. The infection efficiency was ≥ 90% based on fluorescence.
2.3 Transient Re-expression of GFP-Rap1Gap
The gold standard control for knockdown experiments is re-expression of the
protein of interest. Originally, the plan was to virally infect the DCIS Rap1Gap shRNA
cell lines with GFP-Rap1Gap. Many attempts were made to clone GFP-Rap1Gap into
various vectors. Restriction digests and ligation experiments were repeated, and sizes
of the fragments were confirmed to confirm proper ligation. Repeated transformation
experiments in competent bacterial cells yielded 2-3 colonies. Restriction digests of
plasmid DNA isolated from the colonies did not confirm the presence of the full insert.
Different competent cells and different ligation reagents were also used to troubleshoot.
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After 8 months of trial and error, the procedure had to be abandoned and we decided to
proceed with the transient transfection.
Targeted cell lines for transient overexpression of GFP-Rap1Gap were MCF10A,
DCIS.Rap1Gap shRNA and SUM 102. Target cell lines were cultured until 80%
confluent on 35mm dishes. On the day of transfection, media were changed and cells
were given antibiotic free medium. Plasmid DNA and Lipofectamine 2000 were mixed
in Optimem and allowed to incubate at room temperature for 5 mins. Both the solutions
were mixed together and incubated for 20 mins at room temperature. The mixture was
then pipetted and added to the cells. Cells were incubated at 37 o C for 6 h. The
medium were changed and fluorescence was monitored after 48 h.
2.4 Immunofluorescence
Cells growing on rBM were cultured in 35mm dishes. To fix structures, cultures
were briefly washed with pre-warmed PBS and incubated in 4% paraformaldehyde, pH
7.5 in PBS for 30 minutes at room temperature. The fixation was quenched by three
washes with 0.75% glycine in PBS. Then, the cellular structures were permeabilized
with 0.5% Triton X-100 (v/v) in PBS for 10 minutes and blocked with a 1-hour incubation
in immunofluorescence (IF) buffer: 130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4,
0.1% BSA (v/v), 0.2% Triton X-100 (v/v), and 0.05% Tween-20 (v/v), pH 7.5. Structures
were incubated at 4°C with primary antibody in IF buffer overnight in a humidified
chamber. After washing three times with IF buffer, the 3D structures were further
incubated with the fluorescent conjugated secondary antibodies together with other
fluorescent cellular staining reagents (e.g., DAPI, Alexa Fluor-568 phalloidin or Alexa
Fluor-488) at room temperature for 2 hours. After three washes with IF buffer, the 3D
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structures were imaged with a confocal microscope (780; Zeiss, Göttingen, Germany)
as described previously (Yang and Mattingly 2006).
2.5 3D Culture Experiments
Growth of cells in 3D rBM overlay culture (Cultrex, from Trevigen) was assayed
by measurement of volume of structures formed. Fixed cells were imaged with an LSM
780 confocal microscope (Carl Zeiss GmbH, Jena, Germany) using 10x or 63x objective
dipping lenses. Tile-scan mode was used to obtain a 2x2 or 4x4 phase contrast tile
image.
2.6 Morphometric Analysis of Outgrowths of 3D Structures
Differential interference contrast (DIC) images of three random fields at 20x
magnification were used to measure the outgrowths. Outgrowths were defined as small
thorn like structures emanating from the center of the main structure. Two blinded
individuals counted the outgrowths in the images captured at 20x magnification in
accordance with the following parameters: outgrowths >0.5 mm in length and width
were counted. Connections and branches in between the structures were not counted.
Statistical analysis was performed by using one-way ANOVA by GraphPad Prism
software.
2.7 Cell Proliferation Assays
Ten-thousand MCF10.DCIS-dsRed control and MCF10.DCIS-Rap1Gap shRNA
cells were plated in 60-mm dishes. At 48, 96 and 144 h time points, attached cells were
trypsinized and centrifuged at 1000 g. After resuspension, cells were counted with a
hemocytometer via trypan blue exclusion, a common method used to check cell viability
and facilitate counting. Live cells have intact membranes that prevent trypan blue dye

38

from entering. Results were recorded as cell number. Experiments were repeated three
times under same conditions.
2.8 Lysate Preparation for Immunoblotting
To obtain sufficient material for immunblotting from 3D rBM cultures, the overlay
culture process was performed on 60-mm culture dishes. The cultures were briefly
washed with ice-cold PBS (phosphate buffered saline).

3D structures were then

scraped in ice-cold PBS + 5 mM EDTA supplemented with protease and phosphatase
inhibitors and rocked on ice for two hours. 3D structures were centrifuged for 3 min at
1000 g, resuspended and rocked on ice for 30 mins to further dissolve the Cultrex.
After one wash with PBS, the cells were solubilized in a buffer designed for both lysis:
50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10 mM sodium pyrophosphate, 2 mM EDTA,
1% (v/v) Nonidet P40, 1% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol, 2% (w/v) SDS,
50 mM sodium fluoride, 0.2 mM sodium orthovanadate, 0.005% (w/v) bromphenol blue,
and supplemented with protease inhibitor mixtures according to the manufacturer's
instructions. The cell lysates were subjected to brief sonication and heated in 100°C for
5 min. Thirty micrograms of protein were loaded onto 8-12% SDS-polyacrylamide gels
for electrophoresis, ran at 90 V for 2 h. The proteins from the gel were transferred onto
nitrocellulose membrane, blocked with 2% milk solution, and probed for specific target
proteins with corresponding antibodies.
2.9 Preparation of Cytosolic and Nuclear Fractions
Cells were scraped into extraction buffer containing 10 mM Hepes (pH 7.4), 5
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 0.1% NP40 (v/v) and protease inhibitor cocktail
and lysed by using a 26 gauge needle. The lysate was centrifuged for 5 min at 1000 x g
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to yield supernatant (cytosolic fraction) and pellet (nuclear fraction and any unbroken
cells) which was re-suspended in RIPA buffer and sonicated.
2.10 Rap1 Activity Assay
Rap1 activity assays were performed according to the instructions of the
manufacturer (Millipore). Whole cell lysates were prepared by incubating the cells in icecold lysis buffer (50 mmol/L Tris-HCl (pH 7.4), 0.5 mol/L NaCl, 1% NP40, 2.5 mmol/L
MgCl2, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and 10% glycerol).

Lysates were

centrifuged at 14,000 × g for 5 minutes at 4°C. The supernatant was removed and
assayed for protein concentration using the Bio-Rad protein assay.
Thirty microliters of Ral GDS-RBD agarose were added to each tube containing
0.5 mL cell extract and rotated for 45 minutes at 4°C. Pellet beads were collected by
centrifugation (10 seconds, 14,000 × g) and washed thrice with lysis buffer. The beads
were resuspended in 20 μL of 2× Laemmli buffer followed by boiling for 5 minutes.
Samples were run on 15% gel, transferred, and blotted for Rap1. Light exposures of
immunoblot bands for the activity assay and other immunoblots were selected to that
the bands were not saturated. The blots were quantified using densitometry via Multi
Gauge© software.
2.11 Invasion Assays
Thirty thousand cells of MCF10.DCIS and MCF10.DCIS Rap1Gap shRNA were
seeded in serum-free media on BD (Franklin Lakes, NJ, USA) cell culture inserts (8 µm
pore size) pre-coated with Cultrex® (2 mg/ml) and allowed to invade toward media
supplemented with 5% horse serum for 24h. Invading cells were stained and mounted
on slides using the Dif-Quik kit (Thermofisher). Cells were visualized using a Zeiss
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Axiovert microscope, and were counted using ImageJ software. Data were collected
from at least three independent experiments performed in triplicate.
2.12 Live-cell Proteolysis Assays
35-mm petri dishes were coated with 50 µl of rBM containing 25 mg/ml of DQcollagen IV (2.5%) (Invitrogen Life Technologies) and placed in a 37 °C incubator for 15
min to solidify. One thousand cells were plated on top of the rBM and incubated at 37
°C for 30–60 min until they attached. The overlay was added to the cells and cultured
for 8 days. Overlay is defined as assay media with lower concentration of the same
ingredients as phenol red free maintenance media, with 2% horse serum and 2%
Cultrex® (v/v). Phenol red free media is preferred since phenol red interferes with
fluorescence detection. Degradation products of DQ collagen IV (green) were imaged
with a Zeiss LSM 780 META NLO confocal microscope at 488 nm using a 20x and a
63x water immersion objectives. Z- stack images were captured and used to make 3D
reconstructions of the spheroids using Volocity 4.2.0 software (Perkin Elmer, Waltham,
MA). Using the Z-stack, the extent to which the cells invaded into the rBM was
assessed by the presence of fluorescent cleavage products.
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CHAPTER 3: RESULTS
3.1. Rap1Gap protein is highly expressed in MCF10.DCIS in both 2D and 3D
conditions
Previous studies aimed to determine specific gene expression changes common
to three models of DCIS in comparison to MCF10A cells as a model of normal human
mammary epithelium. mRNA seq results showed that Rap1Gap was up-regulated in all
three models of DCIS, compared to MCF10A cells. Multiple studies have focused on
loss of Rap1Gap in acquisition of invasive phenotype in a variety of tissue types. This
dissertation is focused on the loss of Rap1Gap in breast cancer.
Assessment of Rap1Gap protein expression in the MCF10 progression series
was performed in order to validate the initial transcriptome analysis (Fig 1.1). The
immunoblots in Figure 3.1 are of Rap1Gap protein expression in the MCF10
progression series in lysates prepared from 3D and 2D environments. The immunoblot
in Panel A is of Rap1Gap levels from lysates prepared from cells grown in 3D. MCF10A
cells express low levels of Rap1Gap; MCF10.DCIS expressed higher levels, and
MCF10.CA1d, a model of invasive breast cancer, expressed an intermediate level. The
immunoblot in panel B (Rap1Gap levels in lysates harvested from 2D culture) depicts a
similar trend. Rap1Gap protein levels in MCF10.Neo T cells grown in 3D are
significantly higher than lysates grown in 2D environment, but the reason for this
difference is not known. For initial standardization of the antibody for Rap1Gap, lysates
of MCF-7 cells were used as a positive control for immunoblotting [see published AACR
abstract (#3840, 2011) from Prof. Judy Meinkoth], Thus, Rap1Gap protein levels are
low in MCF10A cells, increased in MCF10.DCIS and reduced in MCF10.CA1d cells.
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Figure 3.1: Rap1Gap protein is highly expressed in MCF10.DCIS, with reduced
expression in MCF10.Ca1D, a model of human invasive breast cancer.
A. Lysates were prepared after 8 days of culture in rBM. Immunoblotting was
performed using a polyclonal antibody against Rap1Gap. The molecular weight of
Rap1Gap is 95 kDa. β-tubulin was used as a loading control. B. Lysates prepared from
cells grown in 2D after 3 days in culture. MCF-7 cells were used as a positive control.
β-tubulin served as a loading control. Results are representative of 3 independent
experiments.
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3.2 Rap1Gap is abundantly expressed in luminal hormone responsive cell lines
yet weakly expressed in mesenchymal and metastatic breast cancer cell lines
As mentioned previously, multiple studies have demonstrated loss of Rap1Gap
as a characteristic of acquisition of invasive phenotype. For example Rap1Gap is lost in
aggressive pancreatic and thyroid cancers (Zhang, Chenwei et al. 2006, Zuo, Gandhi et
al. 2010). Basal breast cancer cell- lines express characteristics that are reflective of
invasive metastatic phenotype (Perou, Jeffrey et al. 1999, Chung, Bernard et al. 2002).
Rap1Gap is also highly expressed in differentiated epithelial tissues (Zhang, Mitra et al.
2006, Tsygankova, Ma et al. 2010). Luminal breast cancer cell lines, which are distinct
from basal breast cancer cell lines, preferentially express genes that are associated with
a differentiated phenotype (Beck, Zerler et al. 2001, Feldman, Sementchenko et al.
2003, Charafe-Jauffret, Ginestier et al. 2006). Hence, we hypothesized that Rap1Gap
may be lost in invasive, metastatic breast cancer cell lines and highly expressed in
luminal breast cancer cell lines.
In Figure 3.2, the results show that Rap1Gap is expressed at higher levels in
luminal cell lines (MCF-7 and T47-D), compared to lower expression in the basal breast
cancer cell lines (MDA-MB-231, Hs578t and BT549). In the two DCIS lines derived
from patients (SUM 225 and SUM 102), Rap1Gap levels are strikingly different. SUM
225, a cell line expressing luminal markers (Behbod, Kittrell et al. 2009) and derived
from a chest wall recurrence abundantly expresses Rap1Gap; SUM 102 cells of basal
type derived from a DCIS with micro-invasion (Ethier, Mahacek et al. 1993, Ethier
1996), expresses lower levels of Rap1Gap, which is in agreement with the qPCR data
in Figure 1.2. The stark differences in Rap1Gap expression in SUM 225 and SUM 102
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potentially address the heterogeneity seen in DCIS patients. These potential differences
might be due to transcriptional and/or translational regulation.

For example, qPCR

analysis of Rap1Gap reveals low Rap1Gap transcripts in SUM 102 cells, potentially
leading to low protein levels. SUM 225 cells express higher levels of Rap1Gap, both at
the mRNA and protein levels. This might be due to either concomitant synthesis of more
protein or post-translational stabilization of existing protein.
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Figure 3.2: Rap1Gap expression in breast cancer cell lines.
Lysates were prepared from 3D cultures grown for 8 days on rBM, subject to SDSPAGE and immunoblotting using anti-Rap1Gap antibodies. β-tubulin is a loading
control. Results are representative of three independent experiments. Luminal cell lines
are MCF-7 and T47-D; BT549, MDA-MB-231 and Hs578t are basal cell lines; SUM 225
and SUM 102 are DCIS cell lines.
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3.3. Rap1Gap is found in the nuclear and cytosolic fractions in the MCF10 series
Rap1Gap is known to play a role in the maintenance of adherens junctions and
cell-ECM attachments (Tsygankova, Ma et al. 2010) characterizing it as a cytosolic
protein.

Staining

of

Rap1Gap

in

colon

and

thyroid

tissue

samples

(http://www.proteinatlas.org/ENSG00000076864-RAP1GAP/tissue) also indicate that
Rap1Gap is located in the cytosol. Images from Protein Atlas were reviewed and
confirmed that Rap1Gap is present in the cytosol. The database mentioned above did
not mention evidence of Rap1Gap nuclear staining. Further analysis by a trained
pathologist is necessary to confirm the presence of Rap1Gap in the nucleus. To
determine the localization of Rap1Gap in the MCF10 series, cell fractionation
experiments were performed on lysates prepared from cells grown in 2D cultures.
Interestingly, as seen in Figure 3.3, Rap1Gap is found in both cytosolic and nuclear
fractions.
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Figure 3.3: Rap1Gap is found in the cytosolic and nuclear fractions.
Cells were grown in 2D for 4 days. Cytosolic and nuclear fractions were processed
according to protocol described in the methods. Both fractions were subject to SDSPAGE and immunoblotted for Rap1Gap, tubulin and H4 (Histone 4). MCF-7 serves as a
positive control. β-Tubulin and H4 were used as controls for loading and to show proper
separation of cytosol and nuclear compartments of the lysate respectively.
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3.4 Rap1Gap knock down in MCF10.DCIS transforms cell morphology from
epithelial to fibroblastic phenotype
Previously, it was observed that Rap1Gap was significantly up-regulated in
MCF10.DCIS and is reduced in MCF10.CA1D cells. Breast cancer cell lines with
mesenchymal characteristics express very low levels of Rap1Gap. Hence, we
hypothesized that knocking down Rap1Gap would confer mesenchymal characteristics
in DCIS. This would include transformation to spindle shaped cells and invasive
phenotype. Lentiviral knockdown experiments with two separate shRNA sequences;
(TTGGTGTGTGAAGACGTCA (kd1) and TCTTCTCACTCAAGTACGA (kd2) were
performed.
Panel A in Figure 3.4 shows MCF10.DCIS cells infected with pSIREN dsRed
lentiviral control (Con) or shRNA 1 (kd1) and 2 (kd2). DCIS cells have an epithelial
phenotype, with wide cell bodies and some cell-cell contacts. Knockdown of Rap1Gap
in DCIS transforms cellular shape to long and spindle like, with less frequent cell-cell
contacts. Panel B is an immunoblot showing robust knockdown of Rap1Gap with two
separate shRNA sequences.
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Figure 3.4: Rap1Gap silencing in MCF10.DCIS transforms cell morphology from
epithelial to fibroblastic phenotype.
MCF10.DCIS cells infected with pSIREN dsRed control (Con) or Rap1Gap shRNA (kd1
and kd2) and were cultured for 3 days in 2D. A. Live Images were taken at 20x
magnification. Scale bar, 50 µm. B. Immunoblot of Rap1Gap knockdown in
MCF10.DCIS cells with two separate shRNA sequences, compared to the lentiviral
control.
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3.5 Silencing of Rap1Gap in MCF0. DCIS leads to increase in cell proliferation
Previous studies have shown that Rap1Gap controls cell proliferation
(Wang, Zhang et al. 2014) and may have tumor suppressor properties. Therefore, in
the context of breast cancer, Rap1Gap may regulate cell proliferation. We hypothesized
that that silencing of Rap1Gap may cause increased proliferation. Ten thousand cells
were plated in triplicate for termination at 48, 96 and 144 h time points.. Here, we show
that DCIS cells devoid of Rap1Gap proliferate at a higher rate. As seen in Figure 3.6, at
48 h time point, there is little difference in cell number in the control line vs. the DCIS
cells transduced with the Rap1Gap shRNA.

By 96 h (4 days), the differences in

increase in proliferation are more evident. At 6 days, in both knockdown lines, mean
cell numbers culminate at 140,000 cells vs. the control line, which reached 40,000 cells
when the experiment was terminated. We speculate that there is little difference in the
cell proliferation between the control cells vs. the DCIS shRNA cells when plated at a
low density. As cells continue proliferating, the increased density of cells might increase
the proliferation rate of the cells with Rap1Gap knockdown, which is reflected at 96 and
144 h time points. Loss of contact inhibition is less likely to be factor, since the cell
density did not reach >100% confluency after 6 days of culture. Thus, silencing of
Rap1Gap in MCF10.DCIS causes increased cell proliferation.
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Figure 3.5: Rap1Gap silencing in MCF10.DCIS leads to increase in cell
proliferation.
Ten thousand cells were plated and allowed to grow for 48, 96 and 144 h in 2D
conditions. Cell numbers were determined by trypan blue exclusion and manual
counting on a hemocytometer. Data are the mean SEM of triplicate samples and are
representative of three independent experiments.
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3.6 Rap1Gap silencing leads to the appearance of invasive outgrowths.
In a 2D environment, MCF10.DCIS cells have an epithelial phenotype,
characterized by wide cell bodies. Under the same conditions, MCF10.DCIS Rap1Gap
shRNA cells acquire a spindle shaped morphology (Figure 3.4). When grown in rBM,
MCF10.DCIS, cells form dense dysplastic structures, reminiscent of DCIS in patients.
We hypothesized that MCF10.DCIS Rap1Gap shRNA cells, when grown in rBM would
exhibit the appearance of outgrowths, a characteristic of invasive phenotype.
MCF10.DCIS lentiviral control and MCF10.DCIS shRNA cells were grown in 3D for 8
days and cells were imaged live. We show that the morphology of 3D structures of
MCF10.DCIS Rap1Gap shRNA is strikingly different. These structures are no longer
dense, and form multicellular invasive outgrowths. Additionally, these structures are
much bigger and appear more disorganized. Figures 3.6.1 and 3.6.2 show the
morphology of DCIS Rap1Gap shRNA cells at 20x and 63x magnification. Figure 3.6.3
panel A shows representative 4x4 DIC images used to quantify the outgrowths. Panel
B is the results of the outgrowth analysis. The purpose of the quantification was to
ensure that the appearance of outgrowths is an effect of Rap1Gap silencing. Some
outgrowths were observed in the control.

The p value of 0.0012 means that the

differences in the number of invasive outgrowths are significant. Thus silencing of
Rap1Gap in MCF10.DCIS induces the appearance of outgrowths, a characteristic of
invasive phenotype.
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Figure 3.6.1: Rap1Gap silencing leads to appearance of invasive outgrowths.
Cells were grown in 3D for 8 days and imaged live. DIC (Differential Interference
Contrast) images with fluorescent overlay of non-infected MCF10.DCIS, lentiviral
control, kd1, kd2. Images were taken at 20x magnification. Scale bar, 50 µm. Images
are representative of at least three independent experiments.
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Figure 3.6.2: Rap1Gap silencing leads to appearance of invasive outgrowths.
Cells were cultured in 3D for 8 days to allow growth of structures. Structures were
imaged live. DIC images (top) are side-by-side comparisons of non-infected DCIS vs.
lentiviral control at 63x magnification. The images in the middle and bottom rows
represent 20x and 63x of same structures side by side. Red squares of outgrowths on
the left show regions of interest and are magnified at 63x magnification on the right.
Scale bar, 50 µm.
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Figure 3.6.3: Analysis of Outgrowths.
After culture in rBM for 8 days, DIC images of live 3D structures, consisting of 16
contiguous fields were taken at 20x magnification. The bar graph represents number of
outgrowths per field (mean + SEM from 3 independent experiments). Outgrowths were
counted by two blinded individuals according to parameters described in the results.
Statistical analysis was performed using one-way ANOVA.
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3.7 Lentiviral silencing of Rap1Gap in MCF10.DCIS leads to reduction of
E- cadherin protein levels and breakdown of adherens junctions
E-cadherin is an important component of adherens junctions, which in some
cases are lost during the transition to an invasive phenotype (Thompson, Torri et al.
1994). One characteristic of invasive breast cancer is reduction in E-cadherin and
breakdown of adherens junctions. We hypothesized that reduction in E-cadherin and
concomitant breakdown of adherens junctions may be a consequence of Rap1Gap
knockdown, via Rap1 deregulation (Balzac, Avolio et al. 2005). In a 2D environment,
DCIS cells containing the Rap1Gap shRNA plasmid acquire a spindle shaped
morphology compared to the lentiviral control (Figure 3.4).
Cells were grown in 3D for 8 days, fixed and stained for E-cadherin in order to
visualize adherens junctions. To confirm reduction in E-cadherin protein levels,
immunoblotting was performed. As seen in Figure 3.7 panel A, adherens junctions are
visible in the lentiviral control (red, stained for E-cadherin). The immunoblot in Panel B
shows robust expression of E-cadherin in the control, with significant reduction in the
knockdown lines (kd1 and kd2). Two exposures of E-cadherin are shown to emphasize
that this protein is reduced, not lost. GAPDH was used as a loading control to confirm
equal protein loading. Thus, lentiviral silencing of Rap1Gap leads to reduction of Ecadherin levels and breakdown of adherens junctions.
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Figure 3.7: Rap1Gap lentiviral silencing leads to reduction of E-cadherin protein
levels and breakdown of adherens junctions.
A. Cells were cultured in 3D for 8 days and fixed. DCIS lentiviral control and DCIS
Rap1Gap shRNA cells were grown on rBM for 8 days and fixed. Images are four
contiguous fields, taken at equatorial position. Red (E-cadherin) is Far Red, pseudocolored. DAPI represents fluorescent detection of DNA. Images were taken at 63x
magnification. Scale bar, 150 µm. B. Cells were grown in 3D for 8 days and harvested.
Lysates were subjected to SDS-PAGE and immunoblotting for E-cadherin and GAPDH
(loading control). Images are representative of three independent experiments.
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3.8 Lentiviral silencing of Rap1Gap in DCIS leads to cytoskeletal remodeling and
vimentin reorganization
Remodeling of the cytoskeleton is a significant part of the invasion process and is
carefully orchestrated (Yamaguchi and Condeelis 2007, Mouneimne, Hansen et al.
2012). We had observed the appearance of invasive outgrowths in DCIS-Rap1Gap
shRNA cells (Figure 3.6.2, red squares), and thus we hypothesized that they would
indicate a significant change in the organization of the actin cytoskeleton. Cells were
grown in rBM for 8 days, then fixed and structures were stained for F-actin. As seen in
Figure 3.8.1, fluorescent probe detection of filamentous actin reveals significant
changes in actin cytoskeleton reorganization. Cortical rings, which are typically present
in MCF10.DCIS, are not present in majority of the structures with the Rap1Gap shRNA
(Figure 3.8.1, Figure 3.8.2).
Vimentin is a well–studied member of the family of the intermediate proteins. It
has been well established that vimentin plays a role in the process of invasion. Hence,
vimentin reorganization may be part of the cytoskeletal reorganization. Cells were
seeded in 3D for 8 days, fixed, and stained with vimentin antibody. As observed in
Figure 3.8.3, in the lentiviral control cells, vimentin is apparently closely associated with
F-actin. However, it appears that brighter staining of vimentin was observed in the
center of the structures in the kd2. The brighter staining in the DCIS Rap1Gap shRNA
cells might signify either higher expression in certain areas of the structure or more
concentration of the protein in the center of the structure. Thus, silencing of Rap1Gap
in MCF10.DCIS causes F-actin and vimentin organization.
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Figure 3.8.1: Lentiviral silencing of Rap1Gap in DCIS leads to cytoskeletal
remodeling.
Cells were grown in rBM for 8 days and fixed. Fluorescent probe detection of
filamentous actin (F-actin, green) and nuclei (blue) in the lentiviral control and kd1 and
kd2 lines that have silenced Rap1Gap expression. Images, taken at 63x magnification,
are collapsed z stacks of overlaid green and blue channels. Images are representative
of at least 3 independent experiments. Scale bar, 50 µm.
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Figure 3.8.2: Lentiviral silencing of Rap1Gap in DCIS leads to cytoskeletal
remodeling.
Fluorescent probe detection of filamentous actin (F-actin, green). Image, taken at 63x
magnification is an expanded image of the kd1, (middle image, top panel of Figure
3.8.1) to emphasize the presence of F-actin stress fibers. The white arrows point to the
stress fibers in the outgrowths. Size bar represents 50 μm.
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Figure 3.8.3:
reorganization.

Rap1Gap lentiviral silencing in DCIS leads to vimentin

3D structures were fixed after 8 days of culture. Then, the structures were stained for
filamentous actin (green), vimentin (magenta) and nuclei (blue). Images, taken at 20x
magnification, are collapsed z stacks. Size bar represents 50 µm. Images are
representative of 2 independent experiments (total of 4 images).
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3.9 Silencing of Rap1Gap in MCF10.DCIS leads to enhanced invasion
Cytoskeleton remodeling is a significant part of the invasion process and is
carefully orchestrated (Yamaguchi and Condeelis 2007, Mouneimne, Hansen et al.
2012). The appearance of invasive outgrowths in DCIS-Rap1Gap shRNA cells were
observed, and we hypothesized that they would indicate a significant change in the
organization of the actin cytoskeleton, leading to invasion.
Invasion assays were carried out. MCF10.DCIS control and MCF10.DCIS
Rap1Gap shRNA cells were serum starved overnight.

Thirty thousand cells were

seeded and allowed to invade through the membrane for 24 h. Cells were fixed and
stained blue. Figure 3.9 shows dramatic increase in invasion by the DCIS knockdown
cells through the membrane when compared to the control. The graph in panel B
depicts mean number of invaded cells per field. Statistical analysis was done using oneway ANOVA, p ≤ 0.05.
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Figure 3.9: Silencing of Rap1Gap in MCF10.DCIS leads to enhanced invasion.
A. Cells were allowed to invade through an 8 um pore membrane for 24 h and fixed and
stained blue. Images, taken at 20x magnification are representative of 15 images per
triplicate, per condition, per experiment.
B. Bar graph represents mean number of
invaded cells. Error bars represent standard error of the mean. Data set is the mean of
4 independent experiments. Statistical analysis was done using one way ANOVA.
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3.10 Lentiviral silencing of Rap1Gap leads to increased collagen IV degradation
Silencing of Rap1Gap resulted in the progression of DCIS to an invasive
phenotype. This was characterized by the appearance of multicellular outgrowths
(Figure 3.6), significant remodeling of actin cytoskeleton and vimentin (Figure 3.8), and
increase in invasion (Figure 3.9). We hypothesized that invasive structures may exhibit
an increase in DQ collagen degradation.
Cells were grown in 3D for 8 days in rBM supplemented with 2.5% DQ collagen
and imaged live. The results in Figure 3.10.1 indicate that the multicellular structures
formed by the DCIS Rap1Gap shRNA cells exhibit an increase in collagen IV
degradation (brighter green fluorescence) compared to the lentiviral control. Collagen
IV degradation appears to be either contained within the cells (as seen in kd2 line) or
occurs pericellularly and dispersed farther across the 3D landscape. This observed
degradation of collagen IV could be due to the activity of proteases, since they are
involved in the malignant progression and play a role in aggressive phenotype (Moin,
Sameni et al. 2012). More studies are needed to further test this hypothesis.
To further analyze the effects of lentiviral silencing on proteolytic degradation, 3D
reconstructions of z stacks (Figure 3.10.2) were made to show depth of collagen IV
degradation. More detailed investigation of green fluorescence of the structures (63x
magnification, collapsed z stacks in Figure 3.10.3) indicates that proteolysis can be
pericellular or within the cell. Thus, lentiviral silencing of Rap1Gap results in increased
proteolysis.
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Figure 3.10.1: Silencing of Rap1Gap leads to increased collagen IV degradation .
Cells were cultured for 8 days in rBM supplemented with DQ collagen. Structures were
imaged live to detect presence of cleavage products (green fluorescence). Blue
represents nuclei. Images, taken at 20x magnification, were taken at equatorial
position. Scale bar, 50 µm.
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Figure 3.10.2: Silencing of Rap1Gap leads to increased collagen IV degradation.
The panels in this figure are 3D reconstruction of z-stacks of the images in Figure
3.10.1. The red is dsRed, a reporter protein for the lentiviral transduction. Blue is
Höechst stain of the nuclei of live cells. Green fluorescence is the result of cleavage of
DQ collagen IV. The yellow color observed in kd2 is co-localization of the red reporter
(dsRed) and green fluorescence as a result of proteolysis. Images are representative of
three independent experiments.
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Figure 3.10.3: Silencing of Rap1Gap leads to increased collagen IV degradation- a
closer look.
Cells were cultured for 8 days in rBM supplemented with DQ collagen. Structures were
imaged live to detect presence of cleavage products (green fluorescence). Blue is
nuclear stain of live cells. Images, taken at 63x magnification are collapsed Z stacks
(top panel). The bottom panels are DIC images overlaid with green and blue, and are
same structures taken at equatorial position. Scale bar, 50 µm.
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3.11 Rap1Gap re-expression in MCF10.DCIS Rap1Gap shRNA cells reverses
invasive phenotype
To further test the role of Rap1Gap in the transition to an invasive phenotype, we
performed rescue experiments. Rap1Gap was re-expressed in the DCIS Rap1Gap kd2
line (which had demonstrated a stronger phenotype in the previous assays: see Figures
3.6.1, 3.6.3 and 3.9). GFP was transfected into DCIS Rap1Gap kd2 shRNA cells. Cells
were allowed to grow in 2D conditions for 3-5 days before imaging and preparation of
lysates. Transfected cells were also trypsinized and seeded directly on rBM, to be
cultured with overlay for 8 days before fixing and staining for F-actin.
Panel A in Figure 3.11.1 shows successful transient transfection of GFPRap1Gap into the kd2 line by assay of the reporter’s green fluorescence. Panel B
shows evidence of robust over-expression of GFP-Rap1Gap compared to the GFPcontrol by immunoblotting for Rap1Gap. Figure 3.11.2 displays fluorescent detection of
F-Actin in DCIS Rap1Gap shRNA cells housing the Rap1Gap over-expression. The
multicellular invasive outgrowths, characteristic of cells with silenced Rap1Gap
expression, were blocked, restoring the dense dysplastic structure and F-actin cortical
rings that are found in MCF10.DCIS.
The overlay DIC image in Figure 3.11.3 is a tiled image of 4 contiguous fields
stitched together to assess the effect of the rescue experiment on other structures in the
area. This is evidence that the rescue experiment, though transient, has consistent
effects over time even though not all cells within a structure retain the GFP reporter
protein. Thus, re-introduction of Rap1Gap DCIS Rap1Gap shRNA cells results in
reversion of invasive phenotype, characterized by re-appearance of cortical rings.
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A

B

Figure 3.11.1: Rap1Gap Re-expression in MCF10.DCIS shRNA.
A. Images are of MCF10.DCIS cells, previously infected with Rap1Gap shRNA2 (kd2)
transfected with the GFP-Rap1Gap over expression plasmid. Images shown are at 20x
magnification of live cells monitored for detection of dsRed (red) and GFP (green).
Images are representative of two separate transfection experiments that were viewed 35 days post transfection. B. Parallel lysates from cultures described in panel A were
prepared and subject to SDS-PAGE and immunoblotting using Rap1Gap and β-tubulin
antibodies. β-tubulin serves as a loading control. Images are representative of at least
three independent experiments.
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A.

B

Figure 3.11.2: Rap1Gap re-expression in MCF10.DCIS Rap1Gap shRNA cells
reverses invasive phenotype.
A. Cells were cultured in rBM for 8 days. The structures were fixed and stained for Factin (magenta) and nuclei (blue). Size bar represents 50 µm. These images, taken at
20x magnification, are representative of 3 independent experiments. B. Expanded
single image (20x magnification) of DCIS Rap1Gap shRNA kd cells transfected with
GFP-Rap1Gap from panel A. Only the magenta signal is shown to emphasize presence
of actin cortical rings (arrows).
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Figure 3.11.3: Rap1Gap re-expression in 3D culture.
Cells were grown on rBM for 8 days. Structures were fixed and stained for F-actin
(magenta) and nuclei (blue). Fluorescent detection of dsRed (red) and GFP (green)
was also performed. Images are 4 contiguous fields stitched together to cover a wider
field. Size bar is 150 µm.
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3.11.1 Re-expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells partially
restores E-cadherin levels and adherens junctions
The previous results (Figure 3.11.2) have indicated that Rap1Gap re-expression
leads to restoration of the dense and compact phenotype and actin cortical rings that
are characteristic of MCF10.DCIS cells in rBM culture.

We have also shown that

lentiviral silencing of Rap1Gap leads to marked decrease in E-cadherin and breakdown
of adherens junctions (Figure 3.7). We therefore wanted to investigate whether Ecadherin is re-expressed upon re-introduction of GFP-Rap1Gap.

Transfected cells

were seeded in 3D and allowed to grow for 8 days. Structures were fixed, processed
and stained for E-cadherin. As seen in Figure 3.11.4 panel A, and Figure 3.11.5, reintroduction of Rap1Gap in the kd2 line partially restores adherens junctions.

The

immunoblot in Figure 3.11.4 panel B shows increase in E-cadherin protein levels
following re-expression of Rap1Gap toward the level in control MCF10.DCIS cells. Reexpression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells results in partial
restoration of E-cadherin levels and adherens junctions.
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A

B

Figure 3.11.4: Re-expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells
partially restores E-cadherin levels and adherens junctions.
A. Cells were cultured in 3D for 8 days. Structures were then fixed and stained for Ecadherin (magenta) and nuclei (blue). Images taken at 20x magnification. Scale bar
represents 50 µm. B. GFP-Rap1Gap transfected cells were seeded in rBM for 8 days.
Lysates were prepared and subjected to SDS-PAGE and immunoblotting for Rap1Gap
and β-tubulin (loading control).
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Figure 3.11.5: Re-expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells
partially restores E-cadherin levels and localization.
Shown in magenta, fluorescent probe detection of E-cadherin in DCIS Rap1Gap shRNA
cells transfected with GFP-Rap1Gap that had been cultured in 3D for 8 days. Image is
a single and expanded version of the previous image in Figure 3.11.4 (middle image,
bottom row, A) to emphasize the localization of E-cadherin. Arrows point to localization
of E-cadherin.
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3.12 Lentiviral silencing of Rap1Gap in MCF10.DCIS causes an increase in Rap1
activity
Given that Rap1Gap is a negative regulator of Rap1, we reasoned that
knockdown of Rap1Gap would result in an increase in Rap1 activity. Cells were grown
in 2D for 5 days or until 70% confluency and serum starved overnight. Rap1 activity
assays were performed to detect active Rap1. As seen in Figure 3.12, modest Rap1
activity is observed in the control. Rap1 activity was increased in both of the DCIS
Rap1Gap shRNA lines (kd1 and kd2) and MCF10.CA1d. In addition, re-expression of
GFP-Rap1Gap caused a reduction in Rap1 activity. Panel B shows densitometry
analysis of active Rap1. We show that while silencing of Rap1Gap in MCF10.DCIS
increases Rap1 activity, re-expression of Rap1Gap reduces Rap1 activity.
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A

B

Figure 3.12: Lentiviral silencing of Rap1Gap in MCF10.DCIS causes an increase in
Rap1 activity.
A. Cells were grown until 70% confluency and serum starved overnight. Total Rap1 was
used to verify even loading of lysate used in the actity assay. B. Densitometric scans of
active Rap1 and total Rap1. Ratio of Rap1 GTP vs total Rap1. Error bars represent
standard deviation. Data taken from two separate experiments.
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3.13 Rap1Gap silencing in MCF10.DCIS causes increase in ERK1/2 MAPK
activation
Previous immunohistochemical studies show increased MAPK/ ERK1/2 signaling
in breast cancers compared to normal tissue via IHC (Sivaraman, Wang et al. 1997),
and that primary tumors of node positive patients have relatively higher ERK1/2
activation (Mueller, Flury et al. 2000). Hence, we hypothesized that Rap1Gap silencing
may result inERK1/2 MAPK activation.
Cells were grown in rBM for 8 days and lysates were harvested, subjected to
SDS-PAGE and immunoblotting ERK1/2. The results in Figure 3.12, panel A, show
increased phosphorylation of ERK1/2 in MCF10.DCIS cells with silenced Rap1Gap
expression (lines kd1 and kd2) grown in 3D. An even more robust increase in ERK1/2
phosphorylation was observed in MCF10.Ca1D cells. Panel B is box-whisker plot of
ERK1/2 activation in lysates harvested from 3D conditions. One-way ANOVA statistical
analysis was performed with a p value = 0.0006. Thus, silencing of Rap1Gap in
MCF10.DCIS results in increase in ERK1/2 activation.

78

Figure 3.13: Rap1Gap knockdown in MCF10.DCIS causes increase in ERK1/2
MAPK activation.
A. Lysates were prepared from cells were grown in rBM for 8 days and subjected to
SDS PAGE and immunoblotting. The blot was first probed for ppERK1/2 and then
stripped and reprobed for total ERK1/2. B. Box whisker plot shows densitometry % ratio
of phosphorylated ERK1/2 vs. Total ERK1/2 from immunoblots from three separate
experiments.
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CHAPTER 4: DISCUSSION
4.1 NGS, qPCR validation, and immunoblotting of Rap1Gap
This dissertation project aimed to delineate the role of Rap1Gap in the
progression to invasive breast cancer by using the MCF10 progression series, in the
context of 3D. Previous data from NGS studies revealed Rap1Gap was consistently upregulated in MCF10.DCIS and two other DCIS lines- SUM 225 (derived from a chest
wall recurrence) and SUM 102, an extensive primary DCIS with micro-invasion (Kaur,
Mao et al. 2013), compared to MCF10A cells, a model of non-transformed breast
epithelium. Further mining of the NGS data revealed significantly enriched common
frameworks (as referenced in Table 1), with a 336 fold enrichment. This suggests that
up-regulation of Rap1Gap is a pivotal part of the DCIS signature.
Validation of NGS results via qPCR show that Rap1Gap transcripts are low in
MCF10A and are increased in MCF10.DCIS and SUM 225 cells. However, Rap1Gap
transcripts are low in SUM 102 cells, which is not in agreement with the initial
transcriptome analysis. There are several explanations for such a difference. One could
be that while NGS was performed on RNA of cells grown in 3D, the qPCR analysis was
performed on RNA from cells grown in 2D. This is not surprising, as several instances
of differences in gene and protein expression in 2D and 3D are documented. For
example, in several epithelial ovarian cancer cell lines, β-catenin and BRCA1 were
upregulated in 2D vs 3D environment (Lee, Mhawech-Fauceglia et al. 2013). Higher
expression of cleaved caspase-3 is observed in 3D structures compared to 2D
monolayer culture (Lee, Mhawech-Fauceglia et al. 2013). Additional examples such as
differences in drug sensitivity, differentiation, etc. in the breast cancer models are
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mentioned in section 1.7. A potential technical difference worthy of mention is the
passage number of SUM 102 cells used in both the mRNA seq and qPCR analysis
might be different, resulting in the difference in the results. Another technical difference
is the probes/primers used in the mRNA seq and qPCR analysis, which would target
different exons of the same gene.
In lysates prepared from cells grown in 3D, Rap1Gap protein levels are also low.
This implies post-transcriptional regulation of Rap1Gap. One possible explanation is
that in the breast, Rap1Gap might be subject to proteasome degradation (Wang, Zhang
et al. 2014).
Immunoblotting results show that MCF0A cells express little Rap1Gap, whereas
it is increased in MCF10.DCIS. Compared to lysates extracted from cells grown in 2D,
Rap1Gap levels in MCF10.Neo T cells are significantly higher. This is interesting, since
MCF10.Neo T cells are a model of transformed epithelial cells. MCF10.Neo T cells
were transformed by transfection with mutated H-Ras (Dawson, Wolman et al. 1996). A
possible explanation is that increase in Rap1Gap might initially antagonize
transformation initiated by Ras. This would be consistent with models where Rap1 is an
antagonist of activated Ras (Tsygankova, Prendergast et al. 2007) and the data that
decrease and increase of Rap1 Gap levels increases and decreases Rap1 activity
levels, respectively (Figure 3.12). Down regulation of Rap1Gap leads to activation of
ERK1/2/MAPK

(Figure

3.13),

which

may

correlate

with

invasive

phenotype

(Tsygankova, Prendergast et al. 2007). Rap1Gap levels are reduced in MCF10.CA1D
cells (Figure 3.1). These findings led us to hypothesize that reduction of Rap1Gap
would play a role in the progression to invasive breast cancer.
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Interestingly, rather than overexpression of Rap1Gap, there has been interest in
loss of Rap1Gap in cancer. For example, studies show that down-regulation of
Rap1Gap has been linked to invasion and EMT in multiple cancers (Zhang, Chenwei et
al. 2006, Zhang, Mitra et al. 2006, Zheng, Gao et al. 2009, Tsygankova, Ma et al. 2010,
Zuo, Gandhi et al. 2010). There is one published study that mentions mutations of
unknown significance have been observed in breast cancer (Sjoblom, Jones et al.
2006). We show that the loss of Rap1Gap may act as a switch in the progression to
invasive breast cancer. I show that down-regulation of Rap1Gap via lentiviral silencing
leads to increased Rap1 and ERK1/2 MAPK activation.

Cells acquire an invasive

phenotype, characterized by extensive cytoskeletal remodeling and enhanced invasion.
4.2 Rap1Gap is decreased in invasive breast cancer cell lines
Protein expression of Rap1Gap is increased in DCIS and decreased in invasive
breast cancer cell lines. Some invasive breast cancer cell lines (i.e., MDA-MB-231,
BT549, and Hs578t) exhibit a mesenchymal phenotype in 2D and stellate phenotype in
3D. We hypothesized that MCF10.DCIS cells, which exhibit an epithelial phenotype
characterized by wide cellular bodies and some adherens junctions, would acquire a
fibroblastic phenotype when Rap1Gap is silenced. Cells acquired a spindle shape
(Figure 3.4), with observed reduction in E-cadherin as a result of lentiviral silencing
(immunofluorescence images and immunoblot in Figure 3.7). In a 3D environment,
MCF10.DCIS cells form compact dysplastic structures that model DCIS in vivo.
Adherens junctions (visualized as the localization of E-cadherin, a major component of
adherens junctions) and cortical rings (F-actin) are visible in these structures when
assayed by immunofluorescence. The MCF10.DCIS cells transduced with Rap1Gap
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shRNA acquire a starkly contrasting phenotype. The majority of the structures with the
Rap1Gap shRNA form long invasive outgrowths, signifying reorganization of F-actin that
enables cell elongation and directional motility (Thiery and Sleeman 2006, Yilmaz and
Christofori 2009, Yilmaz and Christofori 2010). Thus, lentiviral silencing of Rap1Gap in
DCIS leads to at least two phenotypic changes: reduction of E-cadherin and F-actin reorganization.
Such an array of phenotypic changes would be consistent with the characteristics
of EMT. There are three types of EMT. Type 1 EMT occurs in implantation,
embryogenesis and organ development; Type II occurs in tissue regeneration and
organ fibrosis; Type III is reported in cancer (Kalluri and Weinberg 2009). In this
discussion, the focus is on type III EMT, which is most germane to cancer. EMT is
described as a complex, transient and reversible process, characterized by the loss of
epithelial characteristics (such as cell–cell attachments, adhesion, and apical–basal
polarity) and the gain of mesenchymal characteristics (such as increased motility,
invasive properties, and a spindle-like morphology) (De Craene and Berx 2013). Studies
have suggested that loss of functional E-cadherin contributes to EMT, where epithelial
cells exhibit loss of cell-cell adhesion, increased motility and invasiveness (Thompson,
Torri et al. 1994).

Depletion of Rap1Gap in DCIS caused a reduction in E-cadherin

and dissolution of adherens junctions.
4.3 Silencing of Rap1Gap in MCF10.DCIS leads to cytoskeletal remodeling
In addition to alterations in adherens junctions, MCF10.DCIS Rap1Gap shRNA
cells exhibit invasive outgrowths and distinct cytoskeletal remodeling. Epithelial cells
possess apico-basal polarity which helps anchor them to the basement membrane;
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changes from apico-basal polarity to front-rear polarity occur during EMT (Lamouille, Xu
et al. 2014).

Since the outgrowths appear flattened (as depicted in the 3D

reconstructions), it is possible that the transition to front-rear polarity is occurring, and
could be further investigated.
Vimentin has been widely reported as a marker of EMT (Mendez, Kojima et al.
2010), and in breast cancer, vimentin is found to be highly expressed in high-grade
ductal carcinomas (Liu, Zhang et al. 2013). Vimentin cannot be used as an EMT marker
in this project. MCF10.DCIS cells already abundantly express vimentin. Increase in
vimentin expression as a result of silencing of Rap1Gap in MCF10.DCIS was not
confirmed. In addition to F-actin reorganization (immunofluorescence images, Figure
3.8.2), we show reorganization of vimentin occurs as a result of Rap1Gap silencing
(immunofluorescence images, Figure 3.8.3). Here, we emphasize that in these studies,
vimentin is re-organized in DCIS Rap1Gap shRNA cells. In the future, EMT could be
confirmed by evaluating the emergence of quintessential EMT markers such as Ncadherin, Twist, Snail or Zeb (Sanchez-Tillo, Liu et al. 2012) via immunoblotting or other
methods.
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4.4 Silencing of Rap1Gap leads to enhanced invasion in MCF10.DCIS
Given the observed cascade of phenotypic changes that have been elicited by
the silencing of Rap1Gap in MCF10.DCIS, we hypothesized that the 3D structures
formed by DCIS Rap1Gap shRNA cells may be invasive. The results from invasion
assays performed (Figure 3.9, panel A) show a significant increase in invasion when
Rap1Gap is silenced.

One observation is that there was a very small number of

invading MCF10.DCIS cells. This phenomenon is in agreement with previous work,
which shows evidence of some invasion by MCF10.DCIS, both in vivo and in vitro
(Miller, Santner et al. 2000, Li, Mullins et al. 2008). The number of DCIS Rap1Gap
shRNA cells that invaded was significantly higher than the control. The invasion assay
was performed in a semi-3D environment, with a coating of 2 mg/ml Cultrex®. The
results of the invasion assay indicate that the cells are motile and are able to move
through the Cultrex® and the pores of the membrane.
4.5 Silencing of Rap1Gap in MCF10.DCIS leads to increased collagen IV
degradation
We have shown that re-organization of F-actin and dissolution of adherens
junctions is associated with the invasion process of MCF10.DCIS cells when Rap1Gap
is silenced. This finding led us to question another interesting aspect of the invasion
process- remodeling by proteases. Given the stark phenotypic changes acquired by
Rap1Gap silencing in MCF10.DCIS cells, and given the observed enhanced invasion
capability, we hypothesized that increased degradation of type IV collagen would play a
role in invasion, and that silencing of Rap1Gap in MCF10.DCIS would lead to increased
proteolysis.
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In the breast, the basement membrane (BM) is the main ECM that interacts with
the luminal and myoepithelial cells of the breast duct. It is primarily made up of entactin,
proteoglycans, laminins and collagen type IV (Oskarsson 2013).

We showed that

Rap1Gap silencing in MCF10.DCIS cells enhanced intracellular degradation of collagen
type IV (Figure 3.10.1, Figure 3.10.2 and Figure 3.10.3). Many proteases are involved in
the remodeling of the ECM. In breast cancer; for example, the participation of cysteine
cathepsins has been reported (Sameni, Moin et al. 2000) (Curino, Engelholm et al.
2005). The type of protease involved here is yet to be confirmed and characterized, and
is a potential focus of future projects. Some studies have shown that Rap1Gap plays a
role in metastasis and extravasation via inside-out signaling of the integrins, particularly
β-1 integrin (Kato, Liao et al. 2012) in melanoma. This is particularly intriguing because
independent studies have elegantly reported that β-1 integrin promotes collagen type IV
degradation in breast and prostate cancers cells, and that reduction of β-1 integrin
expression and function reduced degradation of dye quenched collagen IV and invasion
(Sameni, Dosescu et al. 2008). Even though the proteolysis assay was performed over
a period of 8 days, it complements the results of the invasion assay. We hypothesize
that the cells secrete proteases to move through the rBM.
4.6 Re-expression of Rap1Gap leads to reversal of invasive phenotype
The cascade of phenotypic changes that silencing of Rap1Gap has elicited in
MCF10.DCIS has been addressed. As a control, to confirm whether these changes are
due to reduction in Rap1Gap, rescue experiments were performed. We transiently reintroduced GFP-Rap1Gap into the DCIS Rap1Gap shRNA#2 (kd2) cells (Figure 3.11.2).
Re-introduction of Rap1Gap inhibits the formation of invasive outgrowths.

The
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structures formed are round and compact, and the F-actin cortical rings are present.
Additionally, we also show that E-cadherin levels increased and adherens junctions are
partially restored (immunofluorescence images and immunoblot in Figure 3.11.4).
4.7 Rap1Gap limits Rap1 and ERK1/2 MAPK activation
The

results

in

Figure

3.12

show

that

DCIS

cells

transduced

with

Rap1GapshRNAs exhibit higher Rap1 activation, and that Rap1 activation is reduced
following re-expression of Rap1Gap. There is also a significant increase in ERK1/2
MAPK activation in the knockdown cells grown in 3D compared to the control (Figure
3.13). ERK1/2 MAPK signaling is stronger in the shRNA#2 (kd2) compared to Rap1Gap
shRNA#1 (kd1). Previous studies from our laboratory have confirmed the presence of
activated H-Ras in MCF10.DCIS (Li and Mattingly 2008). This is expected because
MCF10.DCIS is isogenic to the MCF10.NeoT cell line (see section 1.2 for more
information), which harbors the constitutively active T24-H-Ras (Dawson, Wolman et al.
1996). Since H-Ras is already constitutively active in MCF10.DCIS, the assumption is
that DCIS Rap1Gap shRNA cells also harbor constitutively active H-Ras. Since ERK1/2
is further activated in the DCIS Rap1Gap shRNA cells, we conclude that Rap1 and
Rap1Gap might participate in downstream signaling, between H-Ras and ERK1/2.
Rap1Gap and Rap1 may regulate ERK1/2 by antagonizing signals relayed by H-Ras.
4.8 Alternative mechanisms
Other mechanisms have been proposed to delineate the role of Rap1Gap in
cancer progression. For example, studies show that overexpression of Rap1Gap in
pancreatic cancer cells lines (Zhang, Chenwei et al. 2006) resulted in inhibition of FAK
activation and cell spreading without changes in ERK1/2/MAPK phosphorylation. On the
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contrary, studies in melanoma show that Rap1Gap over-expression leads to reduced
ERK/MAPK phosphorylation (Zheng, Gao et al. 2009). Previous studies in different
cancers have reported that blockage or RNAi of ERK1/2 inhibits migration and invasion
in prostate and human osteocarcinoma cells respectively. (Si, Peng et al. 2012, Li, Li et
al. 2013). In the context of ductal breast cancer, ERK1/2 also mediates invasive breast
ductal cancer cell migration and invasion (Ma, Lan et al. 2012).

Our findings are in

agreement with these reports. Other studies have also shown that Rap1 could exert its
effects through Src and FAK. For example, depletion of Rap1Gap in colon cancer cells
induces increase in Src and FAK activation (Tsygankova, Ma et al. 2010). In addition to
the regulation of E-cadherin, inside-out signaling via the integrins, which link the ECM to
the actin skeleton at focal adhesion sites, is also regulated by Rap1, via Src activity
(Hynes 2002). We investigated Src phosphorylation profiles in MCF10.DCIS vs
MCF10.DCIS shRNA cells, which are discussed in Chapter 5.
Rap1 may regulate recycling, avidity and affinity of the integrins that are
associated with the actin cytoskeleton, including α3β1, α4β1, αLβ2, αIIbβ3 (Bos, de Bruyn
et al. 2003, Caron 2003, Dustin, Bivona et al. 2004, Bos 2005). Studies in pancreatic
cancer cells support the role of Rap1Gap in the regulation of integrin activation (Zhang,
Chenwei et al. 2006). Thus, Rap1Gap plays a pivotal role in integrating cell-cell
adhesion and ECM (extracellular matrix) attachment in both normal and malignant
conditions.
4.9 Other GAPs, Rap1Gap2
Previous studies have shown that various GAPs, related to Rap1Gap, are
implicated in proliferative disorders that are similar to cancer. For example, mice
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deficient in Spa-1 develop a spectrum of myeloid disorders that resemble chronic
myeloid leukemia (Ishida, Kometani et al. 2003). Another member of Rap1Gap family,
E6TP1 (Singh, Gao et al. 2003), contributes to cervical cancer and other cancers
associated with chronic human papilloma virus infection. It is targeted for ubiquitin
mediated degradation by viral E67 oncoprotein.
The biological functions of Rap1Gap2 are not widely studied. Studies on
Rap1Gap2 have involved elucidating its potential role in platelet aggregation
(Hoffmeister, Riha et al. 2008, Neumuller, Hoffmeister et al. 2009), axonal outgrowths in
olfactory sensory neurons (Sadrian, Cheng et al. 2012) and sex specific association of
asthma incidence in Latina females (Myers, Scott et al. 2014). In the context of cancer,
IHC analysis shows Rap1Gap2 has been shown to be moderately or highly expressed
in

thyroid

cancer,

lobular

and

ductal

carcinomas.

(http://www.proteinatlas.org/ENSG00000132359-RAP1GAP2/cancer).
In summary, lentiviral shRNA silencing of Rap1Gap in MCF10.DCIS induced
increase in cell proliferation, Rap1 and ERK1/2/MAPK activity, appearance of
outgrowths, extensive cytoskeletal reorganization, increase in proteolytic degradation of
collagen IV and acquisition of invasiveness.

Re-expression of Rap1Gap in

MCF10.DCIS-Rap1GapshRNA cells reduced Rap1 activity and suppressed the
development of invasive outgrowths in 3D structures. Thus, reduction of Rap1Gap in
DCIS may act as a switch to progression to an aggressive phenotype via deregulated
Rap1 and ERK1/2/MAPK activation.
This is the first mechanistic study of Rap1Gap in breast cancer. We have
developed a model in which over-expression of Rap1Gap may be linked to pre-
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malignant progression of breast cancer, whereas subsequent reduction in Rap1Gap
may act as a switch to invasive phenotype. As depicted in the model in Figure 4,
Rap1Gap protein levels are highest at DCIS stage. Upregulation of Rap1Gap protein in
DCIS correlates with E-cadherin delocalization and leads to decreased Rap1 and MAPK
activation. Down-regulation of Rap1Gap is proposed to be a molecular switch for
progression to invasive ductal carcinoma. Loss of Rap1Gap leads to increase in Rap1
and ERK1/2 /MAPK activation, weakening of cell-cell junctions, cytoskeletal remodeling
and invasion.

Subsequently, increased cell motility and invasion will ensue. Re-

expression of Rap1Gap causes reversal of the invasive phenotype, which includes
reappearance of cortical rings, partial restoration of E-cadherin expression and
localization consistent with adherens junctions.
Despite the improvement in detecting DCIS, our understanding of the molecular
evolution in DCIS is scarce. The results obtained from this study may lead to diagnostic
tools that can be used to discern the difference between DCIS lesions that remain
indolent and those that are likely to progress.
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Figure 4: Model. Rap1Gap protein levels culminate at DCIS stage. The over
expression of Rap1Gap protein in DCIS leads to E-cadherin delocalization, decrease in
Rap1 and ERK1/2 activity. Downregulation of Rap1Gap is a molecular switch for
progression to invasive ductal carcinoma, occurring through dramatic increase in Rap1
and ERK1/2 activation. Invasive phenotype, characterized by appearance of
multicellular outgrowths, weakening of adherens junctions, extensive cytoskeletal
remodeling ensues. Re-expression of Rap1Gap inhibits manifestation of the invasive
phenotype via decrease in Rap1 activity and inhibition of appearance of invasive
outgrowths.

91

CHAPTER 5: OTHER DIRECTIONS
5.1 The original hypothesis- Rap1Gap and Src
The original hypothesis of this dissertation was that loss of Rap1Gap, leading to
activation of Rap1 and Src kinase, drives the transformation of DCIS to invasive
carcinoma via deregulation of epithelial junctions and cell matrix attachments.
5.1.1 Src Kinase
Src is a non-receptor protein tyrosine kinase that transduces signals that are
involved in the control of a variety of cellular processes such as proliferation,
differentiation, motility, and adhesion (Gelman 2011). Src was initially identified by
Peyton Rous in 1911 as the transforming agent in chicken sarcomas. Since then, a
whole family of Src kinases has been discovered. Src family kinases play a critical role
in cell adhesion, invasion, proliferation, survival, and angiogenesis during tumor
development (Lutz, Esser et al. 1998). Overexpression or high activation of Src kinase
occurs frequently in tumor tissues and they are central mediators in multiple signaling
pathways that are important in oncogenesis (Lutz, Esser et al. 1998). Activation of Src
occurs as a result of disruption of the negative regulatory processes that normally
suppress Src activity (Bjorge, Jakymiw et al. 2000). In epithelial cells, activation of Rap1
is associated with increased Src kinase activity (Retta, Balzac et al. 2006). Disruption of
adherens junction and enhanced cell matrix adhesion are associated with increased or
over activated Src (Bailey, Kelly et al. 2009). In epithelial cells, as depicted in Figure
5.1, strong activation of Rap1 by E-cadherin is associated with and controlled by Src.
In addition to the regulation of E-cadherin, inside-out signaling via the integrins, which
link the ECM to the actin skeleton at focal adhesion sites, is also regulated by Rap1, via
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Src kinase activity (Hynes 2002). Specifically, Rap1 may regulate recycling, avidity and
affinity of the integrins that are associated with the actin cytoskeleton, including α3β1,
α4β1, αLβ2, αIIbβ3 (Bos, de Bruyn et al. 2003, Caron 2003, Dustin, Bivona et al. 2004,
Bos 2005). Studies in pancreatic cancer cells support the role of Rap1Gap in the
regulation of integrin activation (Zhang, Chenwei et al. 2006). Additionally, studies in
colon cancer cells highlight the downstream of action of Rap1Gap to Src; in Rap1Gap
depleted cells, Src activity was increased (Tsygankova, Ma et al. 2010). Thus, these
studies lead me to hypothesize that Rap1Gap may play a pivotal role in integrating cellcell adhesion and ECM attachment in both normal and malignant conditions via Src, in
the realm of breast cancer.
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Rationale: Rap1Gap and Src together play a role in the maintenance of adherens
junctions

Figure 5.1: Pictorial depiction of Rap1 and Src and their role in the maintenance
of adherens junctions in epithelial cells.
Rap1 is diffusely distributed into the cytoplasm. Activation of Rap1, associated with Src
(circled in red) activation leads to weakening of cell-cell junctions. E-cadherin, β-catenin
and p120 catenin localization are altered, leading to weakening of the adherens
junctions. Image taken with permission from Balzac, F., Avolio, M., Degani,S.,
Kaverina, I. Torti,M,. Silengo, L, J. Small, V., Retta, S. F. J Cell Sci 2005;118:47654783.
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5.1.2

Src

activation

profiles

are

dramatically

different

in

2D

vs.

3D

microenvironments
Based on previous reports, we hypothesized that Rap1Gap down regulation
leads to Src activation and acts as an impetus for the acquisition of invasive phenotype
in DCIS. On the contrary, the results show the opposite of this original hypothesis.
Figure 5.2 shows immunoblots of Src phosphorylation profiles in the MCF10 series – in
2D vs. 3D conditions. Phosphorylation of Src at tyrosine-416 has been linked to its
activation (Harvey, Hehir et al. 1989). Here, in panel 2A, in lysates prepared in 2D
conditions, we show that Src is phosphorylated in MCF10A and MCF10.Ca1d cells.
However, there is little apparent difference in Src phosphorylation in one of the DCIS
Rap1Gap shRNA lines (kd1) compared to the MCF10.DCIS control.
Figure 5.2 panel B shows a dramatic change in Src phosphorylation in the
MCF10 series in lysates harvested from 3D cultures.
phosphorylated Src.

MCF10A cells exhibit robust

DCIS Rap1Gap shRNA #1 (kd1) and DCIS Rap1Gap shRNA #2

(kd2) have lower Src phosphorylation profiles, with a slightly higher Src phosphorylation
in kd1. There are other notable instances of similar dose-dependent responses between
the kd1 and kd2 in other experiments in this dissertation. In lysates grown in 3D, Src
phosphorylation is higher in the lentiviral control compared to the parental line. This
might be due to an artifact of the viral transduction. This does not change the conclusion
that Src phosphorylation is dramatically reduced in the DCIS cells with the Rap1Gap
shRNA. The differences in Src activation in 3D vs. 2D environments is striking. The
data here reveal down-regulation of Src phosphorylation by Rap1Gap silencing that is
not evident in a 2D microenvironment.

95

The conclusion drawn from this experiment is that in the MCF10 progression
series, Rap1Gap might not work through Src in the process of invasion. There is one
other study done on human alveolar basal epithelial cells (A549 cells) that shows that
cell spreading and focal adhesion formation can be directed by Rap1 without Src
involvement (Ross, Spanjaard et al. 2012).
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A

B

Figure 5.2: MCF10 series cells grown in 2D and 3D conditions reveal stark
differences in Src activation.
A. Lysates prepared from cells grown in 2D conditions and subjected to SDS PAGE
and immunoblotting and detection of perch and total Src. GAPDH was used as a
loading control. B. Cells were allowed to grow in 3D for 8 days and lysates were
prepared and subjected to SDS-PAGE. Immunoblot shows detection of pSrc and total
Src. Results are representative of three experiments.
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5.2 Rap1Gap over-expression in SUM 102 cells
A significant portion of this work revolves around the employment of
MCF10.DCIS as model to demonstrate the potential role of Rap1Gap in the progression
of DCIS. We propounded the idea that depletion of Rap1Gap unleashes the acquisition
of invasive phenotype. As mentioned earlier in this dissertation, SUM 102 cells are
characterized as a DCIS with micro-invasion (Barnabas and Cohen 2013). We have
shown that this basal cell line expresses reduced levels of Rap1Gap (Figure 3.2). Since
SUM 102 is a DCIS with micro-invasion, we reasoned that over-expression of Rap1Gap
would induce morphological and underlying molecular changes that are reminiscent of a
non-invasive DCIS.
The immunoblot results in Figure 5.3 show that robust Rap1Gap over-expression
was achieved. When the cells were monitored post transfection, we observed that the
many of the cells were not viable, and therefore more sensitive to transfection with
plasmid. This might be explained by the effects of over-expression of Rap1Gap on cell
viability and proliferation.

Due to the sensitivity of these cells to transfection with

Rap1Gap, it was not practical to further pursue this part of the project. Further
investigation of the effect of Rap1Gap over-expression on the viability and potential
inhibition of SUM 102 cell proliferation would be needed.
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Figure 5.3: Rap1Gap overexpression in SUM 102 cells.
A. SUM 102 cells were transfected with GFP Rap1Gap as indicated. DIC images of live
cells were taken 3-4 days post transfection. The overlaid green fluorescence shows
GFP reporter of Rap1Gap over-expression. B. After 5-7 days of transfection, lysates
were prepared and subject to SDS-PAGE. Immunoblot of Rap1Gap over-expression in
SUM 102 cells. β-tubulin was used as a loading control.
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5.3 Rap1Gap over-expression in MCF10A cells
As described earlier, both at the mRNA and protein levels, Rap1Gap was
observed to be upregulated in MCF10.DCIS compared to MCF10A cells, a model of
non-transformed mammary gland epithelium. We have presented data that support the
hypothesis that Rap1Gap, when lost, manifests in an invasive phenotype in DCIS.
Additionally, as noted in other studies, Rap1Gap may act as a tumor suppressor
(Zhang, Chenwei et al. 2006). Therefore, we aimed to address the question whether the
observed over-expression of Rap1Gap in DCIS drives the development to DCIS from a
non-transformed state or if it is a tumor suppressive response to the development of
DCIS. Hence, we decided to transiently overexpress Rap1Gap in MCF10A cells, a
model of normal breast epithelium.
The DIC images in Figure 5.4, panel A show that the MCF10A cells transfected
with GFP control form structures that resemble non-transformed MCF10A cells. Panel B
shows an immunoblot of efficient over-expression of Rap1Gap in MCF10A cells.

The

MCF10A cells transfected with GFP-Rap1Gap from structures that appear essentially
similar to the control MCF10A though slightly bigger.

They are not reminiscent of

MCF10.DCIS, which are dense and dysplastic. Unlike MCF10A cells, which form hollow
lumens when grown in rBM, dysplastic structures are characterized by disorganized
nuclei and inability to form lumens. The interpretation of these images does not allow us
to conclude that Rap1Gap overexpression drives the progression towards DCIS. It is
possible that the up-regulation of Rap1Gap is more likely a response to the
development of DCIS; i.e. a potential suppressor of progression to DCIS stage.

100

Figure 5.4: Rap1Gap overexpression in MCF10A cells.
A. Five days after transfection, single cell suspensions were seeded in 3D and allowed
to grow for 8 days. Contiguous DIC 2x2 stitched images were taken to assay a wider
field of cells. Scale bar, 50 µm. B. Cells were transfected with GFP Rap1Gap and
lysates were made and subjected to SDS-PAGE and immunoblotting. GAPDH was
used a loading control.
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The purpose of this study is to determine the role of Rap1Gap in the progression
of DCIS (ductal carcinoma in situ) to IDC (invasive ductal cancer). We employed an invitro three-dimensional (3D) overlay model that provides a physiologically relevant
microenvironment to study mechanisms of malignant progression. Previous studies
from this laboratory aimed to determine specific gene expression changes common to
three models of DCIS- MCF10.DCIS, SUM 102 and SUM 225 in comparison to
MCF10A cells, a model of non-transformed human mammary epithelium.

The

expression of 295 genes was found to be significantly altered, with 63 being increased
in expression in all three DCIS cell lines.
The mRNA-Seq results were further mined by Genomatix analysis to gain an
insight into common frameworks in promoter regions of these 63 up-regulated genes.
244 promoter loci were found to be associated with these 63 up-regulated genes.
Enrichment analysis showed that the common framework RXRF-ZF02-ZF02-PLAG-
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HDBP is highly enriched [336-fold], being present in the promoters of RAP1GAP,
SPRY4 and PDGFB genes.
Rap1Gap is a GTPase-activating protein (i.e., an inactivator) for the small
GTPase, Rap1. It is known to be involved in regulation of cell adhesion and has been
previously studied in pancreatic and thyroid cancers, where a decrease in its expression
has been associated with malignant progression. Immunoblotting results show that in
cells grown in 3D, Rap1Gap levels in MCF10.CA1d cells are reduced compared to
those in MCF10.DCIS cells. Lentiviral shRNA silencing of Rap1Gap in DCIS induced an
increase in Rap1 and MAPK activity, as determined by Rap1 activity assay and
immunblotting for phosphorylated ERK1/2. Confocal immunofluorescence (staining of Factin) of 3D structures and invasion assays reveal appearance of multicellular
outgrowths,

extensive

cytoskeletal

organization

and

increase

in

invasion.

Concomitantly, increase in collagen IV degradation was observed. Lentiviral silencing of
Rap1Gap also resulted in an increase in proliferation. Re-expression of Rap1Gap in
DCIS-Rap1GapshRNA cells reduced Rap1 activity and suppressed the development of
invasive outgrowths in 3D structures. Additionally, adherens junctions and E-cadherin
levels were partially restored. Thus, we conclude that reduction of Rap1Gap in DCIS
acts as a switch to progression to an invasive phenotype via deregulated Rap1 and
MAPK activation.
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